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ABSTRACT 
The dissertation describes asymmetric synthesis towards C29-C34 moiety of fragment A 
of the Antascomicin B and Thermal azole based Claisen rearrangements. In chapter 1, we describes 
asymmetric synthesis towards C29-C34 moiety of fragment A of the Antascomicin B. The non-
immunosuppressant Rapamycin, Ascomycin, and Tacrolimus (FK506), strongly binds with 
FKBP12, the ligand FKBP12 complexes responsible for immunosuppressive activity. 
Antascomicin B structurally related to Rapamycin, Ascomycin, and Tacrolimus (FK506), binds 
strongly to FKBP12, yet does not shown immunosuppressive activity. The ligand FKBP12 binding 
complexes shown to have potent neuroprotective and neurogenerative properties in mouse models 
of Parkinson’s disease. The linear synthesis of C29-C34 moiety of fragment A of the Antascomicin 
B was highlighted through chemical reactions include an Delis Alder reaction, asymmetric transfer 
hydrogenation (ATH), epoxide ring opening reactions.  In chapter 2, we describes novel 
methodologies of preparing 2-butenyl benzothiazole derivatives using aza-Claisen rearrangement, 
through N, S-ketene acetals intermediates. The precursor N-allyl-N, S-ketene acetals were 
prepared in situ from the reaction of N-allyl benzothiazolium salts.  N-allyl benzothiazolium salts 
synthesized by simply alkylated 2-methyl benzothiazole with various allyl bromide derivatives. 
Despite of the traditional approaches, our proposed synthetic methodology of N, S-ketene acetals 
that requires only weak base, possesses broad functional group compatibility, and require no 
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 Organic chemistry is a study of molecules consist of carbon, hydrogen, oxygen and nitrogen 
atoms, provided numerous pharmaceuticals, petrochemicals, agriculture chemicals, and various 
other every day necessary compounds. Synthetic chemistry is the process of building various 
organic molecules ranging from small to macromolecules by utilizing series of chemical organic 
reactions. Synthetic organic chemists have been developing new synthetic methodologies to 
demonstrate the efficient, economic and environmentally safe reaction conditions to build 
molecular complex natural products.1, 2 
         Natural products are macromolecules, which play a pivotal role in drug lead discovery. 
Scientists have been working to isolate biologically active natural products that generally produced 
by living organisms such as plants, bacteria, fungi and marine organisms. The extracted 
biological/chemical compounds were administered to animal models (mouse, rat and genie pigs), 
and identified as biologically active. The molecular structure of these compounds was determined 
experimentally by spectroscopic methods, thus paving the way for their synthesis on a laboratory 
scale.3, 4 
The McIntosh research group involved in the asymmetric synthesis of the natural products 
as well as developing innovative synthetic methodologies for practical and efficient conversation. 
In this dissertation, we have been studied the asymmetric synthesis of the C29-C34 moiety of 
fragment A of the Antascomicin B (Chapter 1), and novel methodologies of preparing 2-butenyl 
benzothiazole derivatives using aza-Claisen rearrangement, through N, S-ketene acetals 





B. Chapter 1: Asymmetric synthesis towards C29-C34 moiety of fragment A of the 
Antascomicin  
I. Introduction 
            Natural product synthesis is a challenging construction of a naturally occurring compound 
in the laboratory starting from simple, commercially available materials. There are several goals 
of natural products total synthesis such as provide additional quantities for biological testing, 
modify the natural product to improve its biological profile, e.g. improve potency, decrease side 
effects, increase metabolic stability, increase solubility, etc. One of the important applications of 
these natural products is to treat several diseases, such as Atherosclerosis (heart disease), cancer, 
parasitic helminthic infections, malaria and autoimmune diseases.3, 4  
          The process of synthesizing a certain molecule involves several steps. First, the structure of 
the desired molecule analyzed carefully in order to search for any vulnerable sites, wherein bonds 
could be broken. This would cause the transformation of the original molecule into smaller 
fragments, which can serve as precursors for the whole process. In total synthesis, desired 
compounds could synthesized as result of building these small fragments together in a variety of 
chemical reaction.5 
         Primarily, my research studies designed for the asymmetric synthesis of the C29-C34 moiety 
of the Antascomicin B (Scheme 1) feasible for scale up, efficient, economic and environmentally 





Scheme 1: Antascomicin B 
 
II. Background: Antascomicin B 
        Sandoz Pharmaceuticals first isolated Antascomicin B in 1996 from Genus Micromonospora, 
which was collected from a soil sample in China.6 The isolated Micromonospora bacterial strain 
found to contain a family of compounds known as Antascomicin A to E. Sandoz Pharmaceuticals 
has conducted an assay to identify active metabolites, which can bind to FKBP12. Over 12000 
bacterial strains from this assay used to measure the strength of binding substrates in comparison 
with FK-506 and Rapamycin. According to the results, Antascomicin strain showed great binding 
affinity to FKBP12 compared to FK-506 and Rapamycin.6   In the process of treating diseases, 
Antascomicin family (Scheme 2) binds with FKBP12, which is an immunophilin. Consequently, 
Antascomicin family shows a greater specificity in binding to activity domains. One characteristic 
of this family, which has generated considerable interest among the scientific community, is its 
4 
application in regenerating nerve tissues, namely Rapamycin and FK506. In particular, 
Antascomicin B can specifically bind to FKBP12 in the family.  
 
 
Scheme 2: Antascomicin family 
        Besides the family of Antascomicin, in addition, Rapamycin, Ascomycin, and Tacrolimus 
(FK-506) have the potential to bind with FKBP12 (Scheme 3). As per literature, all these 
compounds considered as non-immunosuppressant. Upon bonding with FKBP12, all these 
compounds, except Antascomicin B, become immunosuppressant. They all bind to FKBP12 in the 
same fashion, but differ in terms of activity.  
        Tacrolimus (FK-506)/FKBP12 complex acts as an immunosuppression by blocking T-
lymphocyte activity. As per literature, this caused due to calcineurin, which is a calcium-dependent 
serine phosphate. Calcineurin is responsible for dephosphorylating NF-ATP and OAP (proteins), 
which regulate gene transcription code for inflammatory mediators, namely IL-2 and GM-GSF. 
Inflammatory mediators are essential for the development of immune system.7 
5 
         On the other hand, Rapamycin/FKBP12 complex behaves as an immunosuppression by 
blocking mTOR, a protein that is responsible for controlling the cell growth and proliferation by 
preventing the entry of lymphocytes into the cells.8, 9 
        S.H Snyder group at John Hopkins University School of Medicine discovered that FKBB12 
exists at high concentration in brain than immune system.8 This study could serve as a guiding 
principle to the work outlined here in order to investigate the role of immunophilins in certain 
regions of the neural system. The study has showed that Rapamycin/FKBP12 and FK506/FKBP12 
complexes exhibit neuroprotective and neurodegenerative properties in neuronal system. In 
addition, these complexes have shown to possess immunosuppression, which degrades their ability 
to treat damaged nerves.10, 11 
         Furthermore, Antascomicin/FKBP12 used for treating damaged nerves without exhibiting 
immunosuppression. The hypothesis that Antascomicin and FKBP12 complexes exhibit 
neuroprotective and neurogenerative properties was proved to be true in animal models while 
treating Parkinson’s disease.13 Literature studies indicate that Antascomicin B could be a potent 




Scheme 3: FKBP12 binding domains of Rapamycin, FK506 and Antascomicin B. 
III. Retrosynthesis 
           Retrosynthetic technique is a powerful tool for designing the synthesis of complex 
molecules. The proposed synthesis of Antascomicin B could be achieved by ring closing 
metathesis at C21-C22 with the help of fragment A(C21-C34) and fragment B(C1-C21), which belong 
to the family of Antascomicin B (Scheme 4). In 2004, Fuwa’s group has published preliminary 
studies on C18-C34 fragment of Antascomicin A
14, while Chakraborty et al have published about 
the synthesis of fragments C1-C21
15 and C22-C34.
16 In addition, Stephen Leys’ research group at 
7 
Cambridge University has published the total synthesis of Antascomicin B for the first time in 
2005.17   Their method alongside others involved high load of catalysts, and considered as a major 




Scheme 4: Proposed Antascomicin B retrosynthetic strategy 
 
           The retrosynthetic steps of the of the asymmetric C21–C34 fragment of Antascomicin B was 
well organized by Dr. McIntosh group. The fragment A can be achieved from the pentanoic acid 
derivative by several reaction such as converting into corresponding Weinreb amide and 
hydrogenation using Crabtree catalyst to install stereocenters, allyl diazene rearrangement, 
catalytic hydrogenation, selective deprotection of benzyl protecting group, reduction of alkene and 
followed by Grieco olefination. 
8 
           The pentenoic acid derivative would achieved by Ireland- Claisen rearrangement through 
the allylic ester derivative. The Allylic ester can be synthesized from the epoxy quinol 6.5 through 
the ring opening epoxide reaction, protection of the hydroxyl groups and  propargylation to alkyne, 
BOC protection of the secondary alcohol and followed by acylation gave allylic ester. The epoxy 
quinol 6.5 was achieved from commercially available benzoquinone 6.1 through the 4 steps 
including most significant asymmetric hydrogenation. 
 







IV. Synthetic studies towards the C29-C34 moiety of Fragment A of the Antascomicin B 
 
1. Preliminary studies: 
        The synthetic studies towards the Antascomicin B successfully reported by Dr. McIntosh 
group. According to our recent report about the synthesis of the C21-C34 fragment was limited by 
the lack of an efficient asymmetric route due to one of the key early intermediates, trihydroxy 
cyclohexenone 7.1. At the same time, the asymmetric routes available to make trihydroxy 
cyclohexenone 7.1 included several steps, high enzyme loading, long reaction times and limited 
scale.18-20, 29-31. 
         The ongoing efforts in our lab for the asymmetric synthesis of the Antascomicin B started 
with the commercially available benzoquinone 6.1.  The Diels-Alder reaction conditions were 
utilized to synthesize mesodiketone 6.2 with the benzoquinone 6.1 and freshly clacked 
cyclopentadiene as starting materials. The meso diketone 6.2 converted to epoxy diketone 6.3 in 
excellent yields with help of the epoxidation conditions. The both reactions were developed in 
large scale (100 g) without suffering yield of the reactions. Using Noyori’s Ru (p-cymene) [(S, S)-
TsDPEN] catalyst the epoxy diketone 6.3 was converted to epoxy keto alcohol 6.4 in moderate 
yield with the high enantiomeric ratio (>99 ee). The enantioselectivity of the reaction was 81:19 
er at 5% of the starting material conversation with in 1 hour determined by chiral GC. The 
enantioselectivity of the reaction was achieved 93:17 in 16 hours with the 85% yield. The longer 
reaction times such as 48 hours leads 99.6:0.4 er with the diminishing yields of desired product 
(45%) due to the kinetic resolution. The epoxy keto alcohol 6.4 was converted to epoxyquinol 6.5 
in good yield by the Taylor21 variation of the Lubineau22 procedure for the retro Diels-Alder 
reaction. The retro Diels-Alder reaction was successfully scale up to 20 g without diminishing the 
yields (Scheme 6). 
10 






2. Studies of ring open epoxyquinol:        
 
        Epoxides are useful building blocks in the synthesis of natural products. The epoxide ring-
opening reaction occurs through SN2 reaction under neutral or basic conditions to synthesize diols. 
This reaction leads to 1, 2 substituted products with a trans/anti relationship when a nucleophile 
attack the epoxide carbon. For these reactions, water considered a great solvent among others and 
it produces acceptable yields.23, 24 Jin Qu proposed enantioselective ring opening of epoxide by 
hydrolysis in hot water in the absence of catalyst.25 Also, ring-opening reaction of epoxides or 
aziridines with various types of nucleophiles is a well-studied field. All these studies indicate that 
green solvent (water) considered as the suitable solvent and nucleophile for enantioselective ring 
opening of epoxide.   Literature studies show that the hydrolysis of epoxy cyclohexenone through 
reflux heating in water at 90 oC for four days leads to the formation of enantioselective diols.25                   
To synthesize trihydroxy cyclohexenone 7.1, the epoxy keto alcohol 6.5 treated with water at 90 
oC for 4 days to yield moderate yields. The aromatized byproduct (1, 2, &4-benzenetriol) formation 
was expected in this reaction and this was the one of the potential problems for moderate yield 
(Scheme 7). The desired trihydroxy cyclohexenone 7.1 converts into enol form and dehydration is 
followed to get by product would be the expected mechanism.  
 
               
Scheme 7: Ring opening reaction of asymmetric epoxyquinol moiety 
12 
       To overcome this potential problem, we were introduced useful literature techniques in the 
organic reaction to maximize yields. As of expected mechanism the formation of aromatized 
byproduct need to have slightly acidic medium and in this reaction water acts as acid catalyst, so 
we planned to create a slightly basic medium (used basic buffer) in the reactions conditions to 
mimic the side product (Scheme 8).  This method was not successful to mimic the side product 
formation. Therefore, we planned to monitor the reaction day-to-day. 
 
    
Scheme 8: Compliance of ring opening reaction of epoxyquinol                
          The 10 mg of epoxy keto alcohol 6.5  was taken in NMR tube with 1 mL of deuterated water 
and heated the closed NMR tube for 4 days at 90 oC to track the 1H NMR (Scheme 9 & 10) of the 
crude reaction each and every day. We closely tracked the 1H NMR spectra of crude reaction 
mixture every 24 h and we noticed no side product (1, 2, &4-benzenetriol) presence even after 4 
days of heating. So finally, we came to conclude that the side product formed in process of column 
purification. For the column purification, we treated the silica gel with slightly basic condition (1% 




Scheme 9: Tracking ring opening reaction of epoxyquinol through 1H-NMR 
NMR Study of ring opening epoxide in D2O 
 
      
Scheme 10: Analyzing day-to-day 1H-NMR spectra of the ring open reaction. 
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        From the expected mechanism, the double bond in epoxyquinol 6.5 would help to develop a 
stable aromatized compound (side product) followed by dehydration of enol form of desired 
compound 7.1.  As of literature, the substituted epoxyquinol derivatives gave good yields of the 
hydrogenated products with the Pd metal on carbon.26 The epoxyquinol 6.5 was treated with 
hydrogen gas with Pd metal on carbon was gave no reaction. Therefore, the proposed plan of 
hydrogenated product of epoxyquinol would treated with H20 at 90 
oC for 4 days was obstacle to 
generate good yield of desired trihydroxy cyclohexenone 7.1. 
3. Studies towards the asymmetric trihydroxy cyclohexanone:             
          The enantiopure trihydroxy cyclohexenone 7.1 served as the precursor for the synthesis of 
the fragment A of the Antascomicin B. The free hydroxyl groups needed to survive in order to 
achieve the final Antascomicin B. As of original plan, trihydroxy cyclohexenone 7.1 hydrogenated 
with Pd metals on carbon in methanol, leads to the formation of trihydroxy cyclohexanone 11.1 in 
good yields. As per literature, various protecting groups, such as Acetyl, Benzoyl, Benzyl, Silyl 
ether and TBSCl can used to protect the hydroxyl group in trihydroxy cyclohexanone 11.1. 
Furthermore, hydroxyl cyclohexanone 11.2 was successfully prepared from trihydroxy 
cyclohexanone 11.1 treated with TBSCl as the protective groups, imidazole and DMF as the base 
and solvent, respectively. (Scheme 11).  The overall yield of the 3-step reaction starting from the 
epoxy keto alcohol 6.5 to the hydroxyl cyclohexanone 11.2 was 16.4%. This procedure require 3-
column chromatography purification each after the reaction. As of our investigation, the yield of 
trihydroxy cyclohexenone 7.1 from epoxy keto alcohol 6.5 diminished because of the column 
purification. Therefore, we decided to utilize the crude trihydroxy cyclohexenone 7.1 for further 
reactions without column purification. The crude trihydroxy cyclohexenone 7.1 treated with the 
hydrogenated condition to yield the trihydroxy cyclohexanone 11.1 and the crude trihydroxy 
15 
cyclohexanone 11.1 treated with the TBSCl as the protective groups gave the hydroxyl 
cyclohexanone 11.2 overall 24% yield. The proposed revised synthetic strategy successfully 
demonstrated 7.6% higher yield of hydroxyl cyclohexanone 11.2 with single column 
chromatography versus the traditional 3 continuous step reaction conditions. The purity of the 
hydroxyl cyclohexanone 11.2 compared with the standard molecule and confirmed. 




Scheme 11: Revised synthetic route for asymmetric hydroxyl cyclohexanone moiety  
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V. Future studies: 
 
        The hydroxyl cyclohexanone 11.2, would be valuable intermediate for the asymmetric 
synthesis of the desired fragment A (C21-C34) of Antascomicin B (Figure 12).  The synthetic 
methods developed by colleagues for the efficient construction of fragment A (C21-C34) from 
hydroxyl cyclohexanone 11.2, through various rearrangements, namely Ireland-Claisen and allylic 
diazene rearrangements. The asymmetric synthesis toward the fragment B (C1-C21) was 
commenced with pipecolinic acid, and its synthetic route was traced by Claisen rearrangement and 







Scheme 12: Proposed synthetic steps of Antascomicin B, fragment A. 
 
        As final steps in Antascomicin B total synthesis, fragment A (C21-C34) should conjoin with 
fragment B (C1-C21) to produce compound 13.1. As per literature, the two free hydroxyl groups on 
each fragment can attached by Yamaguchi Lactonization.27 Compound 13.2 could synthesized 
from compound 13.1 by ring closing metathesis28.  The final product, Antascomicin B, could be 
prepared from compound 13.2 by the removal of all protecting groups by universal deprotection 
reaction conditions. (Figure 13). 
17 
 
Scheme 13: Proposed final steps of Antascomicin B total synthesis 
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VI. Experimental section 
   
Cyclopentadiene. The dicyclopentadiene (250 mL) placed in a 1L round bottom flask equipped 
with a magnetic stirring bar. The round bottom flask connected with a vigreux column, which 
attached to a continuous circulating ice water condenser. The flask heated with oil bath at 210 oC 
and the condensation temperature of cyclopentadiene monitored by thermometer. The distillation 
of the cyclopentadiene should not occur above 40 oC on thermometer. The cracked 
cyclopentadiene collected at -78 oC and stored at -78 oC for maximum for 20 days.  
 
 
Meso diketone 6.2.  The p-Benzoquinone (100.00 g, 0.92 mol) and dichloromethane (800 mL) 
was allocated in a 2 L three necked round bottom flask, equipped with a magnetic stirrer bar and 
thermometer. The round flask was cooled to -10 oC with methanol and ice bath. Freshly cracked 
cyclopentadiene (40 mL, 0.46 mol) added over a period of 30 min. A second 40 mL portion of 
cyclopentadiene added in a similar fashion (The cyclopentadiene added in two portions to mitigate 
the dimerization that occurs upon warming to room temperature). The mixture then stirred in the 
ice bath for 1 h and then stirred at room temperature for 1 h. The solvent removed in vacuo and 
the crude brick red oil material purified by recrystallization from hexanes. The light-yellow 
crystals were washed with hexanes, and then dried completely under high vacuum to give meso 
19 
diketone 6.2 as pale yellow crystals (117.7 g, 68%): spectral data matched those previously 
reported.32, 34, 35. 
 
 
Epoxy diketone 6.3. The meso diketone 6.2 (100.00 g, 0.57 mol) and THF (1250 mL) was 
transferred to 2L three necked round bottom flask, equipped with a magnetic stir bar. The H2O2 
(35%, 120 mL) was added dropwise via addition funnel approximately 1 h while the reaction 
mixture stirring at room temperature. To the solution, NaHCO3 (sat., 133 mL) was added dropwise 
via addition funnel approximately 1 h. The reaction mixture stirred for another 2 h and monitored 
starting material consumption by TLC. The solvent was removed in vacuo and the crude material 
(pale white solid) was purified by recrystallization (white solid) from ethanol to give epoxide 
diketone (81.7 g, 75%). spectral data matched those previously reported. 20, 34, 35 
 
 
Ru (p-Cy) TsDPEN: Ru (p-Cy) TsDPEN was prepared by dissolving [RuCl2 (p-Cy)] 2 (1.00 g, 
1.63 mmol) and (S, S) - TsDPEN (1.20 g, 3.27 mmol) in dichloromethane (25 mL) and allowing 
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to stir for 5 minutes. KOH (1.31 g, 2.3 mmol) and water (25 mL) was then added and the mixture 
was allowed to stir for an additional 5 minutes. Reaction was complete when the color turned from 
orange to deep purple. Reaction mixture extracted in dichloromethane, dried over CaH2, and then 
concentrated in vacuo to give Ru (p-Cy) TsDPEN as dark purple crystals (quantitative yield). Data 
matched that previously reported. 33 
 
  
Epoxy keto alcohol 6.4. Ru (p-Cy) (S,S-TsDPEN) (0.42 g, 0.68 mmol, 0.65 mol %) and epoxy 
diketone 6.3 (25.0 g, 0.13 mol) were added to a solution of formic acid (6.75 mL), triethylamine 
(25.0 mL) and acetonitrile (1000 mL) at -10 °C. The reaction mixture allowed to warm to room 
temperature and stirred for 48 h. The mixture was concentrated in vacuo and then stirred for 16 h 
in 40/60 ethyl acetate/hexanes (300 mL) with activated charcoal (1 g). The mixture was filtered 
through a plug of Celite with 40/60 ethyl acetate/hexanes and concentrated in vacuo. At this point, 
the residue could be purified by flash chromatography (20/80 ethyl acetate/hexanes) to give keto 
alcohol 6.4 as colorless crystals (10.12 g, 40%, 99.6:0.4 er). Spectral data matched those previously 






Epoxyquinol 6.5. A solution of monoreduced epoxy keto alcohol 6.4 (20 g, 104 mmol) in diphenyl 
ether (200 mL) was dissolved and stirred at room temperature while degassed with nitrogen for 30 
minutes. The reaction mixture was then heated to 180 oC (still gently bubbling through with 
nitrogen) until decomposition product became a significant spot as monitored by TLC. After 
cooling to room temperature, the reaction mixture poured onto a column of silica gel using hexane 
to elute diphenyl ether solvent. After elution with hexane, the reaction mixture was eluted with 
1/99-9/91 MeOH/CH2Cl2 1% gradient followed by recrystallization with diethyl ether to yield pure 
epoxyquinol 6.5 as white crystals (7.87 g, 60%). Spectral data matched those previously reported. 
20, 34, 35 
 
 
Trihydroxy cyclohexenone 7.1: Epoxyquinol 6.5 (12 g, 79.30 mmol) was distributed in 1 gram 
aliquots to 12 parallel synthesizer tubes and H2O (12 mL) with stir bar. Each tube heated to 90 
oC 
for 4 days on the heating mantle. H2O then co-evaporated with MeCN and the brown residue 
adsorbed on silica gel. The silica gel/residue was added to a silica gel column using CH2Cl2. 
Mixture was eluted with 0/99-10/90 MeOH/CH2Cl2 at 1% gradient. The second fraction was 
collected and recrystallized in EtOH to give trihydroxy cyclohexanone 7.1 (6.03 g, 41.84 mmol, 
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40%) as colorless crystals. M.P. 136-138 oC; [α]23 D -0.885 (c 0.437 1:1MeOH:CH2Cl2); IR (film) 
3400, 2835, 1693. 1H NMR (400 MHz, CD3OD) δ 3.58 (dd, J = 10.87 Hz, 8.28 Hz, 1H), 4.03 Hz 
(d, J = 10.88 Hz, 1H), 4.36 (m, 1H), 6.04 (dd, J = 10.33 Hz, 2.56 Hz, 1H), 6.92 (d, J = 10.33 Hz, 
1.94 Hz, 1H); 13C NMR (400 MHz, CH3OD) δ 70.12, 75.17, 76.99, 124.57, 150.36, 197.21. Anal 
Calcd for C6H8O4: C, 50.00; H, 5.59. Found; C, 49.89; H, 5.65.65. Spectral data matched those 




Trihydroxy cyclohexanone 11.1. A mixture of trihydroxy cyclohexenone 7.1 (5.28 g, 14.17 
mmol) and 10% Pd/C (0.950 g, 0.90 mmol Pd) in dry methanol (100 ml) was stirred under an H2 
atmosphere (1 atm) for 7 h. Following completion of the reaction by TLC, the reaction mixture 
filtered through celite and concentrated. The crude product was purified by flash column 
chromatography on silica gel using 1/99-4/96 gradient of ethyl acetate/hexane, followed by 
recrystallization with cold hexane to give trihydroxy cyclohexanone 11.1 (4.67 g, 12.47 mmol, 
80%) as white crystals. [α]23D = +4.6 (c 0.5 CH2Cl2); IR (film) 3414, 1736 cm-1; 
1HNMR (400 
MHz, CDCl3) δ  1.60 (m, 1H), 2.04 (m, 1H), 2.37 (m, 2H), 2.53 (d, J = 2.53 Hz, 1H), 3.47 (td J = 
9.96, 1.54, 1H), 3.87 (ddd, J = 11.21, 8.67, 4.69, 1H), 4.07 (d, J = 9.77 Hz, 1H); 13CNMR (400 







Trihydroxy cyclohexenone 7.1. The epoxyquinol 6.5 (1 g, 7.9 mmol) was dissolved in 12mL of 
H2O in a pressure with a magnetic stir bar. The pressure tube heated to 90 
oC for 4 days on the oil 





Trihydroxy cyclohexanone 11.1. A mixture of crude trihydroxy cyclohexenone 7.1 (1.14 g, 7.9 
mmol, expected from previous reaction) and 10% Pd/C (0.21 g, 2 mmol Pd) in dry methanol (20 
mL) was stirred under an H2 atmosphere (1atm) overnight. Following completion of the reaction, 








Hydroxy ketone 11.2. The crude trihydroxy cyclohexanone 11.1 (1.14 g, 7.9 mmol, expected from 
previous reaction) in 10 mL dry DMF was added to the solution of TBSCl (3.57 g, 23.7 mmol) 
and imidazole (2.15 g, 31.6 mmol) in dry DMF (20 mL). After stirring at room temperature for 4 
h, the reaction mixture was quenched with ice-cold water, extracted with ether, dried over MgSO4, 
and concentrated in vacuo. The crude product purified by flash column chromatography on silica 
gel using 3:97 ethyl acetate: hexane, followed by recrystallization with hexane to give hydroxy 
ketone 11.2 (0.71 g, 1.9 mmol, 24% over 3 steps).  
Alternatively solution of TBSCl (5.82 g, 38.6 mmol) and imidazole (3.50 g, 51.4 mmol) in dry 
DMF (30 mL) was added to trihydroxy cyclohexanone 7.1 (1.88 g, 12.9 mmol) in 10 mL dry 
DMF. After stirring at room temperature for 4 h, the reaction mixture quenched with ice water, 
extracted with ether, dried over MgSO4, and concentrated in vacuo. The crude product was purified 
by flash column chromatography on silica gel using 3/97 ethyl acetate/hexane, followed by 
recrystallization with cold hexane to give hydroxy ketone 11.2 (2.40 g, 6.42 mmol, 50% single 
step) as white crystals. M.P. 76-78 oC; [α]23 D = +0.084 (c 0.26 CH2Cl2); IR (film) 3414, 1736 
cm-1; 1H NMR (400 MHz, CDCl3) δ 0.06 (s, 3H), 0.14 (s, 3H), 0.16 (s, 3H), 0.17 (s, 3H), 0.92 (s, 
9H), 0.94 (s, 9H), 1.60 (m, 1H), 2.04 (m, 1H), 2.37 (m, 2H), 2.53 (d, J = 2.53 Hz, 1H), 3.47 (td J 
= 9.96, 1.54, 1H), 3.87 (ddd, J = 11.21, 8.67, 4.69, 1H), 4.07 (d, J = 9.77 Hz, 1H); 13C NMR (400 
MHz, CDCl3) δ -5.33, -4.49, -4.44, 18.10, 18.59, 25.78, 25.84, 29.65, 34.67, 35.72, 72.84, 79.71, 
205.66. Spectral data matched those previously reported. 34, 35. 
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C. Chapter 2 












The Claisen rearrangement, discovered in early twentieth century,1 provided a very 
powerful synthetic procedure for carbon-carbon bond formation. Over the past few decades, the 
importance of the reaction has been well known and drawn the attention of numerous research 
groups, which has been reflected in the number of papers published in the literature. The [3,3] 
sigmatropic rearrangement of allyl vinyl ethers, which allows the preparation of γ,δ-unsaturated 
carbonyl compounds (Scheme 1). This reaction was first reported by Ludwig Claisen in 1912,1 




Scheme 1: Simplest aliphatic Claisen rearrangement 
 
Eschenmoser2, Johnson3 and Ireland4 extensively expanded the initial Claisen 
rearrangement (Scheme 2).  As of their findings, the ketene acetal formation was fundamental for 
the [3,3] sigmatropic rearrangement and it was achieved by in situ. 
 The significant difference from the simplest allyl-vinyl ether framework with presence of 
the heteroatom at the C2 position, which result in formation of corresponding amides, esters and 
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silyl esters called Eschenmoser2, Johnson3 and Ireland4 Claisen variations respectively. Another 
variant arises from the replacement of the oxygen atom by a nitrogen atom called the aza-Claisen 
rearrangement5 (also known as 3-aza-Cope or amino-Claisen rearrangement) (Scheme 2).   
 
Scheme 2: Variations on Claisen rearrangement system 
 
In 1964, Eschenmoser2 observed the [3,3] rearrangement of N,O-ketene acetals to yield  
γ,δ-unsaturated amides. The N,O-ketene acetals was generated by reacting allyl alcohols with N,N-
dimethylacetamide dimethyl acetal (Scheme 3). 
In 1970, Johnson3 reported the synthesis of trisubstituted alkenes. The allyl alcohol was 
heated with excess ethyl ortho acetate with presence of catalytic acid yields ortho ester and losses 
the ethanol to generate the ketene acetal, which undergoes sigmatropic rearrangement leading to 
γ,δ-unsaturated ester.  
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In 1972, Ireland4 reported the rearrangement of allyl trimethylsilyl ketene acetal. The 
ketene acetal was generated in situ from allylic esters with LDA base to corresponding silyl enolate 
to yield γ,δ-unsaturated carboxylic acids upon heat (Scheme 3). 
 
  
Scheme 3: Variations on Claisen rearrangement system 
 
In acyclic systems, Claisen rearrangement occurs preferentially through a chair-like 
transition state over the boat-like transition state, however, the rearrangement happened through 
boat transition state in the presence of steric effects.6 The Claisen products were formed when the 
steric substituents were present at C1 and C6 positions of the parent allyl vinyl ether frame through 
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both chair and boat like transition states (Scheme 4). The relative configuration of the newly 
formed stereocenters determined by configuration of the double bond, and the chair or boat 
confirmation of the transition states. 
Scheme 4: Transition states and products of the Claisen rearrangement  
 
              The variation on initial Claisen rearrangements were well studied and reported in 
literature. Our primary moto in this project is to develop a feasible methodology of Claisen 
rearrangement without harsh condition to possess broad functional group compatibility.  The 
accomplishment of this goal will provide a practical and scalable synthetic method for building 
biological important macromolecules. 
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II.   Significant reports of Claisen rearrangements 
1. Robert E. Ireland: The Claisen rearrangement from N, O-ketene acetals 
Ireland et al adopted the concepts of the Claisen rearrangement to synthesize substituted 
dihydro-1,3-oxazine derivatives 3.4.7 Among the various Claisen rearrangement procedures, the 
excess utilization of precursors for the 1,5-diene system (in-situ formation of ketene acetals) was 
necessary to produce γ, δ unsaturated acid equivalents. Here in the report, the economical 
utilization of γ-hydroxyl amide 3.1 was used to convert dihydro-1,3-oxazine derivatives 3.4 by 
series of the 3-step reaction performed in one pot thus providing good yields.  
 
Scheme 5: The Claisen rearrangement from N, O-ketene acetals 
 
The γ- hydroxyl amides 3.1 treated with thionyl chloride to yielded ketene acetal precursor 
oxazonium salt 3.2. The oxazonium salts treated with lithium diisopropylamide (LDA) to generate 
the ketene acetals 3.3 in situ. Heating reaction at 190 0C for 1 hour gave the corresponding γ,δ-
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unsaturated oxazine derivatives 3.4. The two-alkyl groups on the either terminus of the ketene 
acetals might responsible for the considerable low yield of desired product (Scheme 5). 
 
2. Jack E. Baldwin: [3,3] Sigmatropic rearrangement of electron rich olefins 
As of the Baldwin’s report in 1974, N-substituted benzothiazole derivatives were studied 
for competing [1,3] and [3,3] sigmatropic rearrangements.8  He discovered that the two competing 
reaction pathways for the rearrangement of diaminofulvalene were dependent on reaction 
temperature and the benzothiazolium N-substituents. Reactions conducted at higher temperatures 
with the N-allyl benzothiazolium salts 4.1 yielded predominantly [3,3]-rearrangement products 
4.3, and the reactions that were run with highly radical stabilizing N-alkyl groups predominantly 
yielded radical [1,3]-rearrangement products 4.4. On the other hand, N-benzyl benzothiazolium 




Scheme 6: [1,3] & [3,3] Sigmatropic rearrangement of electron rich olefins 
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3. Mark J. Kurth: Asymmetric synthesis through aza- Claisen rearrangement 
In 1985, Kurth et al described first asymmetric synthesis for the 2-substitued-4-pentenoic 
acid 5.5 by aza-Claisen rearrangement of N-allyl-N, O-ketene acetals 5.29 (Scheme 7). 
 
Scheme 7: Asymmetric synthesis through aza- Claisen rearrangement 
 
The intermediate (Z)-N, O-ketene acetal is preferred over the (E)-N, O-keteneacetal 
formation due to nonbonding interactions (Scheme 7). The (Z) - N, O-ketene acetal face selectivity 
of two transition states called as syn or anti. Then anti face intermediate preferable over the syn 
face intermediate occurs at sp3-hybridized nitrogen center due to steric interactions. The facial 
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conversion of anti (Z)-N, O-ketene acetal from syn (Z)-N, O-ketene acetal presumably increased 
diastereoselective products (Scheme 8). 
 
 
Scheme 8: syn vs anti face intermediates of aza- Claisen rearrangement 
 
They extended the same methodology to synthesize asymmetric 3-substituted-4-
pentenoic acid derivative 6.410 (Scheme 9). The contention between E/Z-allyl olefin moiety, the 
transition state of the (Z)/ (E)-allyl olefin of N, O-ketene acetal face selectivity and the transition 






Scheme 9: Asymmetric synthesis through aza- Claisen rearrangement 
          
         As of his findings, the chair/boat transition state selectivity is a crucial factor for the 
asymmetric synthesis of 3-substituted-4-pentenoic acid derivative.  In either alkene geometry, the 
chair-like transition state is more favorable than the boat-like transition state because the 
substituents of the nascent C-C bond in chair-like transition state are nearly staggered while in 
boat-like transition state are approximately eclipsed.  However, the energy differences between 
the chair/ boat transition states on Z-alkene geometry are higher than the energy differences in E-
alkene geometry. The diastereoselectivity outcomes as 76:24 for (E) N-allyl-N,O-ketene acetals 
and 89:11 for (Z) N-allyl-N,O-ketene acetals when R=iPr (Scheme 9). In general, the higher 
chair/boat selectivity contributing the diastereoselectivity outcomes and here the boat confirmation 
destabilized by the eclipsing interactions (Scheme 10). 
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Scheme 10: Transition states of aza- Claisen rearrangement 
 
Both cases of asymmetric synthetic studies revealed that the (Z) - N, O-ketene acetal face 
selectivity is a consequence of the interconversion to anti face selectivity responsible for the good 
diastereoselective for synthesis of the 2-substitued-4-pentenoic acid derivatives. On other hand, 
the asymmetric synthesis of the 3-substitued-4-pentenoic acid derivatives reflected the impact of 
chair/boat transition states selectivity.  
                                          
4. Jon A.Tunge: Regio-and diastereoselective decarboxylative coupling of Heteroaromatic 
alkanes. 
In 2007 Tunge and Waetzig has demonstrated the high regio- and diastereoselectivity 
synthesis of 2-butenyl azole derivatives (aza-Claisen products) 7.4 using a Pd catalyst through the 
intermediate N-allyl-N, O-ketene acetals 7.311. In this method, the aromatic ester 7.1 utilized as a 
starting material, and the Pd (0) catalyst used to form the Pd (II)-allyl complex, which fragmented 
to aryl carboxylate and Pd (II) allyl complex 7.2. The fragmented aryl carboxylate and Pd (II) allyl 
complex recombined through the electron rich nitrogen with organometallic complex and 
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proceeded the decarboxylative dearomatization, which leads to the necessary ketene acetal 7.3. 
The ketene acetal 7.3 was rearranged to compound 7.4 by restoring the lost aromaticity via [3,3]-
sigmatropic rearrangement. Tunge proposed that the rearomatization was the reason for modest 
reaction temperature at 80 0C needed for rearrangement products compared to traditional Claisen 
rearrangement temperatures at 200 0C. The relative configuration of the newly formed 
stereocenters was revealed to be anti, consistent with a boat-like transition state coupled with a Z- 
configuration for the keteneacetal in aza Claisen precursor 7.3 11 (Scheme 11). 
 
Scheme 11: Regio-and diastereoselective coupling of Claisen type rearrangement 
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5. Rolf Breinbauer: Pd catalyzed allylation of imine heterocycles through aza-Claisen 
rearrangement. 
Breinbauer utilized the aza-Claisen rearrangement of N-allyl, N, X-ketene acetal (X= N, 
S, O, C) in the allylation of the nitrogen containing heterocycles.12 The oxazoline derivative 
8.1 was utilized as a test substrate of imine moiety to study the leaving group, solvent, 
temperate and influence of ligand for the parent allylation reaction. Initials studies revealed 
that the combination of allyl acetate, 4 mol% Xantphos ligand and 2 mol% palladium catalyst 
for excellent yield of the allylation of imine heterocycles through aza-Claisen rearrangement. 
These optimized conditions used to test various imine heterocycles with scope and limitation 
of the reactions (Scheme 12). 
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Scheme 12: Pd catalyzed allylation of imine heterocycles through aza-Claisen rearrangement. 
 
     As per Breinbauer’s proposed mechanism, the η3-Pd (II)-allyl complex 9.3 forms from allyl 
acetate 9.1 with the Pd (0) catalyst, due to the displacement of the acetate anion. The intermediate 
iminium ion 9.4 formed from the alkylation of the η3-Pd (II)-allyl complex 9.3 with the electron 
rich imine 9.2. The deprotonation of the acidic CH bond with the acetate anion leads to the 
formation N-vinyl allyl amine (ketene acetal) (9.5), which undergoes through [3,3]-sigmatropic 
rearrangement catalyzed by Palladium12 (Scheme 13). 
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Scheme 13: Proposed mechanism of aza-Claisen rearrangement 
 
         Unfortunately, all the aforementioned literature of the Claisen rearrangement variations 
were suffering from at least one or more limitations.  The Claisen rearrangement methods involved 
with the oxazine derivatives (Ireland and Kurth) employed stoichiometric amounts of strong base. 
Strong base requires cryogenic conditions and possess functional group limitations in the presence 
of alcohols, primary and secondary amines, and various acidic functionalities. In Baldwin’s report, 
the Claisen product diaminofulvalene had a limited functionality because of the homodimer 
starting material. The palladium catalyzed (Tunge and Breinbauer) Claisen variations suffers from 
several important limitations. The use of Pd (0) catalyst, for instance, raises functional group 
compatibility issues, as substrates containing terminal alkynes or other moieties that can engage 
in oxidative addition like vinyl or aryl halides, which would presumably not tolerated. As per 
Breinbauer’s report, the alkylation with several heterocycle derivatives such as benzothiazole and 
benzoxazole were not successful with the applied reaction condition to furnish the Claisen type 
rearrangement. 
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With compilation of aforementioned literature precedence, we have couple of concern such as  
1. Why only the strong bases (LDA and n-BuLi) employed for the ketene acetals generation 
(Ireland and Kurth)? What happen if we use weak base for the ketene acetals formation?  
2. Why Tunge’s palladium catalyzed Claisen variations did not success with parent 
rearrangement? 
All these questions complemented us to testify the benzothiazole based Claisen rearrangements 
(alternative approach to the Ireland-Claisen rearrangement) to find the experimental evidence.  
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I. Alternative approach to the Ireland-Claisen rearrangement 
 
             Our interest in Claisen rearrangement started with Ireland-Claisen rearrangement reaction. 
In Antascomicin B synthesis, the Ireland-Claisen rearrangement reaction employed in synthesis of 
-unsaturated acid 10.2 from corresponding allylic ester 10.1. In this synthesis, the allylic ester 
derivatives 10.1 employed with strong base, as only deprotonation that occurred has led to the 
desired ketene acetal 10.3 to make the Claisen rearrangement product 10.2. In general, the acidic 
functionalities with greater pKa values such as alcohols, terminal alkynes and other enolizable 
carbonyl-containing groups would need to protect or would otherwise suffer deprotonation in 




Scheme 14: Ireland-Claisen rearrangement in Antascomicin B synthesis 
 
            This limitation prompted us to consider alternative ways of accessing -unsaturated acids 
using milder conditions that would allow for a broader functional group tolerance. We began by 
considering the preparation of the simplest possible -unsaturated acid with two adjacent 
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stereocenters 11.5. Traditionally, the acid derivative can accessed through the Ireland-Claisen 
rearrangement of ketene acetal 11.4. The ketene acetal 11.4 formed from the allyl acetate 11.3 in 
the presence of the strong base. Allyl acetates 11.3 generally synthesized by acylation of allyl 
alcohols 11.1 with acyl halides 11.2. We reasoned that acid derivative 11.5 could also be deliver 
by hydrolysis of 2-butenyl benzothiazole 11.8, which is the rearrangement product of ketene acetal 
11.7. This option could be useful if ketene acetal 11.7 could formed under milder conditions than 
its analog 11.4b. The benzothiazolium salt 11.6 simply prepared by alkylation of benzothiazole 
with allyl halide derivatives. In order to test our hypothesis, we turned our attention to the 
preparation of quaternary salts derived from 2-methylbenzothiazole (Scheme 15). 
 
 
Scheme 15: Alternative to the Ireland-Claisen rearrangement 
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II. Results and discussion: 
 
1. Reaction conditions and optimization. 
 
            Our interest apropos Claisen rearrangement started with the N-allyl benzothiazole salts 
derived from 2-methyl benzothiazole 12.1. The preparation of N-allyl benzothiazolium salt 12.2 
well studied by Dr. McIntosh group’s former member Silvana S. Dormi.13 In her study; the N-allyl 
2-methyl benzothiazolium tosylate 12.2 achieved in quantitative yields by treating 2-methyl 
benzothiazole with allyl tosylate at 120 0C for 1 hour.  In contrast to traditional column purification, 
the benzothiazolium salt purified by simple trituration of the crude reaction material with the 
diethyl ether to remove excess starting materials (Scheme 16). 
 
Scheme 16: Alkylation of benzothiazole  
          The studies towards the ketene acetal formation was uncertain and literature revealed that 
2, 3-dimethylbenzothiazolium perchlorate 12.3 was treated with aqueous base yields dimer 12.6.14 
As per the proposed mechanism, the dimerization 12.6 was the result of desired ketene acetal 12.4 
addition its precursor 12.3. The quaternary salt 12.5 was deprotonated at C2 resulted the dimer 
12.6. Owen15 developed condition to minimize the side reaction of dimer formation with 
employing a large excess (8.0 eq) of the base, tetramethylguanidine (TMG). As of Owens report 
the addition of sodium hydride (1.5 eq) with using a non-polar solvent (e.g. benzene) and slow 
addition of the salt 12.3 to ice-cold TMG-NaH-solvent mixture to lower the concentration of the 
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salt in solution, which led to minimizing dimer formation 12.6. The reaction was continued to stir 
at 0 oC for 1 hour and warmed to room temperature over 20 hours. Filtration followed by solvent 
removal gave the corresponding ketene acetal 12.4 (Scheme 17). 
 
Scheme 17: Dimer formation as side product  
 
The ketene acetal 13.1 formation from the N-allyl benzothiazolium salt 12.2 was 
extensively studied by Dormi stared with the Owen’s conditions. The investigation revealed that 
the 1 equivalent of tetramethylguanidine (TMG) was enough to deliver the corresponding ketene 
acetal 13.1 from the N-allyl 2-methylbenzothaizolium salt 12.2. The ketene acetal heated at 180 
0C for 1 hour, which leads to the final product in good yield13.  By using tetramethylguanidine 
(TMG) as base for ketene acetal formation, the Claisen rearrangement compound synthesis 
depends on heating method and temperature, which influenced the outcome of the reaction after 
removal of the TMGH+ salt through Celite® filter (Scheme 18). 
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Scheme 18: Demonstrated Claisen rearrangement sequence 
 
              As per Dormi’s Claisen rearrangement, dimer 14.2 formation from the benzothiazolium 
salt (12.2) was the main side product that was observed at heating temperatures lower than 160 0C. 
In presence of the tetramethylguanidine (TMG), the benzothiazolium salt 12.2 was in equilibrium 
with its ketene acetals 13.1, which in turn was in equilibrium with the dimer benzothiazolium salt 
14.1 through unreacted benzothiazolium salt. The dimer benzothiazolium salt 14.1 was in 
equilibrium with the stable dimer of the benzothiazole 14.2 in presence of the base (Scheme 19).13 
 
 
Scheme 19: Dimer formation as side product in Claisen rearrangement 
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             The fact that the dimer product slowly converted into Claisen rearrangement product at 
greater than 180 0C can explained through an acid catalyzed mechanism (Scheme 20).13  
In presence of an acid, dimer 14.2 was in equilibrium with its conjugate acid 14.1, which in turn 
was in equilibrium with ketene acetal 12.2 and its corresponding conjugate acid 13.1. Eventually, 
ketene acetal 12.2 irreversibly rearranged with the consequent Claisen product 13.2. We believe 









2. Study of the reaction scope. 
 
The optimized conditions for the Claisen rearrangement were successfully developed, and 
we began studying the scope of the reaction. The studies started with the alkylation of 2-methyl 
benzothiazole with commercially available allyl bromide derivatives at 120 0C for 1hour without 
solvent to yield the benzothiazolium salts. The allyl bromide derivatives included 2,3-
dibromopropene, 2-methyl-3-bromopropene, 1,1-dimethyl-3-bromopropene and geranyl bromide 
which provided benzothiazolium salts 16.1, 16.2, 16.3 and 16.4 with moderate to excellent yields. 
The benzothiazolium salts treated with tetramethylguanidine (TMG) in toluene for 15 min and the 
TMGHBr salt removed by Celite® filter. The crude filtrate transferred to sealed tube and heated 
at 180 0C for 1 hour to yield corresponding Claisen rearrangement products. Column 
chromatography was required to purify the products 16.5, 16.6, 16.7 and 16.8 in moderate to good 





Scheme 21: Scope of proposed Claisen rearrangement 
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           The commercially available cinnamyl chloride was unreactive in the alkylation but was 
treated with sodium bromide in acetone to yield cinnamyl bromide (Finkelstein variation on 
Wagner reaction).17 Alkylation of 2-methyl benzothiazole with the cinnamyl bromide successfully 
produced the N-cinnamyl benzothiazolium bromide 17.1 salt in 82% yield (Scheme 22). 
 
                
Scheme 22: Synthesis of N-cinnamyl benzothiazolium bromide salt 
 
             The compound cis-4-chloro-2-butene-1-ol also converted to cis-4-bromo-2-butene-1-ol by 
the Finkelstein variation on Wagner reaction17 methodology yielded 78%. The alkylation of the 2-
methyl benzothiazole with the cis-4-bromo-2-butene-1-ol gave the corresponding benzothiazolium 
salt 18.1 in 48% with 20% recovery of the starting materials (Scheme 23). 
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Scheme 23: Synthesis of (N)-cis-2-butenol benzothiazolium salt 
 
            Myrtenol is a commercially available allyl alcohol, which easily converted to the allyl 
bromide derivative in 90% yield through the reaction conditions with PBr3.
19 The Myrtenol 
bromide alkylated with 2-methyl benzothiazole at 120 0C to produce N-myrtenyl benzothiazolium 
bromide salt (19.1) in 48% yield (Scheme 24). 
 
                             
 
Scheme 24: Synthesis of N-myrtenyl benzothiazolium salt 
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          After obtaining N-cinnamyl benzothiazolium bromide salt 17.1, (N)-cis-2-butenol 
benzothiazolium bromide salt 18.1 and N-myrtenyl benzothiazolium bromide salt 19.1 in good 
yields, we treated with the optimized conditions for the Claisen rearrangement and produced the 
corresponding products 20.1, 20.2 and 20.3 with moderate to good yields, following column 
purification (Scheme 25). 
 
 
Scheme 25: Expanded scope of Claisen rearrangement 
 
            So far, the proposed Claisen rearrangement methodology explored with unprotected 
alcohol, aliphatic, and aromatic groups. This methodology further need to be modify for the 
exploration of acidic functional groups such as aldehydes, amides, alkynes and many more. 
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            Due to the limited supply of commercially available allyl halide derivatives, we decided to 
synthesize the allyl halide derivatives with having the board functional groups for their feasibility 
in the Claisen rearrangement. The conventional synthesis of various complex allyl bromide were 
unsuccessful and we were in need to derivatization of N-allyl benzothiazolium salts for the Claisen 
rearrangement. As we mentioned previously, the N-allyl benzothiazolium salts triturated with ether 
has led to the pure salts from the unreacted starting materials. The advantage of purifying salts 
without performing a column chromatography prompted us to produce the N-allyl 
benzothiazolium bromide 21.1 derivatives by utilizing the N-allyl benzothiazolium bromide 12.3 
with cross metathesis conditions (Scheme 26). The metathesis attempts with N-allyl 
benzothiazolium bromide slats and different olefin derivatives might have advantage of 
demonstrating broad functional group compatibility, and simple purification method. 
 
 
Scheme 26: Proposed synthesis of N-allyl benzothiazolium derivatives 
 
             At this point, we need to ascertain the conditions for the metathesis reaction of olefin 
derivatives with benzothiazolium salts. A literature studies revealed first ever self-metathesis of 
N-alkenyl amine salts and cross metathesis of N-alkenyl amine salts with the acrylate derivative.20 
The optimized reaction conditions for tandem self-metathesis with 5 mol% Ru catalyst, ethyl 
acetate, excess acrylate, triflate as counter ion and reflux reaction for 24 hours gave the good yield. 
The choice of the solvent and counter ion were the most important controlling factors due to 
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solubility20 (Scheme 27). The optimized reaction conditions were utilized to study the cross 
metathesis of the N-allyl amine triflate salts with the acrylate derivatives. This investigation 




Scheme 27: Self-metathesis Vs cross metathesis of alkenyl amine with acrylate 
             
            According to Robinson’s report, the self-metathesis product of the unsaturated ammonium 
salts 22.2 competes with the cross-metathesis product unsaturated ester ammonium salts 22.3. The 
molar ratios of the N-alkenyl ammonium salts 22.1 with acrylate derivatives less than the 1:10 
responsible for the major self-metathesis product 22.2. On the other hand, the molar ratios of 
ammonium salts with the acrylate derivative more than 1:10, yields major cross metathesis product 
22.3. The large excess (20 eq) of the acrylate derivative with the N-alkenyl ammonium triflate salt 





Scheme 28: Cross metathesis of alkenyl amine with acrylate 
 
           Based on closest preceding literature20, we started metathesis reaction of N-allyl 
benzothiazole bromide salt with the allyl alcohol in excess gave unidentified products. We 
explored the reaction with different olefin moieties such as 3-butenol, allyl acetate, 2-vinylpyridine 
and 1-vinyl pyrrolidinone which gave unidentified products. The metathesis reaction conditions 
modified with the catalysts Grubbs -II and Hoveyda Grubbs -II, at reaction temperature of 40 0C 
and 65 0C, and solvents such as methanol and dichloromethane. However, these attempts were 
unsuccessful for the metathesis reaction (Scheme 29). The unsuccessful attempts of metathesis of 
benzothiazolium slats with olefin derivatives guided us to synthesize the various allyl bromide 
derivatives through metathesis conditions. The following alkylation of allyl bromides with 2-
methyl benzothiazole for benzothiazolium slats preparation, which might provide an advantage for 
the functional group compatibility in the proposed Claisen rearrangement. 
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Scheme 29: Metathesis attempts with N-allyl benzothiazolium and olefin derivatives 
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         The allyl bromide and allyl chloride with the different olefin derivatives utilized 
metathesis conditions for the synthesis of allyl halide derivatives successfully synthesized in 
moderate to good yields. The metathesis reaction with allyl bromide derivatives was little more 
complicated when compared to allyl chloride derivatives21 (Scheme 30). 
 
 
Scheme 30: Synthesis of allyl halides using alkene metathesis. 
 
         According to the literature, 21 the allyl bromide was reacted with different olefin derivatives 
such as allyl alcohol, acrylonitrile and styrene in presence of the Hoveyda Grubbs-II catalyst to 
yield the unidentified product (Scheme 31). At this point, the metathesis reaction involved with 
the allyl bromide yielded unidentified products and we decided to explore optimized reaction 
conditions for the synthesis of allyl bromide derivatives. 
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Scheme 31: Synthetic attempts for allyl halide derivatives 
 
            The commercially available 1,4-dibromo-2-butuene was testified for the alkylation with 2-
methyl benzothiazole, successfully yielding the mono alkylated benzothiazolium salt 27.1 in 82%. 
The benzothiazolium salt 27.1 was treated with the various nucleophiles utilizing under 
nucleophilic substitution conditions for the derivatization of benzothiazolium salts 27.2 gave 
unsuccessful result 27.2 (Scheme 32). 
 
Scheme 32: Alkylation of benzothiazole with 1,4-dibromo-2-butene 
61 
            The mono alkylation of the 1,4-dibromo-2-butene with the 2-methylbenzothiazole 
prompted us to synthesize various allyl bromide derivatives through nucleophilic substitution 
reaction with 1,4-dibromo-2-butene. We adopted the reaction conditions from the nucleophilic 
substitution with allyl bromide23 to synthesize complex allyl bromide derivatives from 1,4-
dibromo-2-butene. The 2-hydroxybenzothiazole, 4-acetamidophenol, vanillin and diethyl methyl 
malonate were treated with 1,4-dibromo-2-butene for the nucleophilic substitution in the specified 
conditions to produce the corresponding complex allyl bromide derivatives with moderate to good 








             By having complex allyl bromide derivatives in hand, we demonstrated the alkylation 
reaction under optimized conditions with 2-methyl benzothiazole and allyl bromide derivatives 
28.1, 28.2, 28.3 and 28.4 that gave successful benzothiazolium salts 29.1, 29.2, 29.3 and 29.4 with 
moderate to good yields (Scheme 34). 
 
Scheme 34: Synthesis of complex benzothiazolium salts 
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             The complex benzothiazolium salts 29.1, 29.2, 29.3 and 29.4 tested with the optimized 
conditions for the Claisen rearrangement and successfully gave the corresponding products 30.1, 
30.2, 30.3 and 30.4 moderate to good yields. The results, suggest that the various functional groups 
such as aldehyde, amide and alcohols tolerated with optimized conditions. As of now, we clearly 
demonstrated that the functional groups such as unprotected aldehydes, unprotected alcohols, 
unprotected amides, esters, ethers, and unsaturated aliphatic were tolerated in the proposed Claisen 
rearrangement (Scheme 35). 
 
 
Scheme 35: Complex Claisen rearrangement products 
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3. Iterative Claisen rearrangement: 
 
            Iterative synthesis is a useful technique in the organic synthesis, to allow the similar 
reaction sequences for the stepwise synthesis of repeated building blocks. In the process of iterative 
Ireland-Claisen rearrangement, the Claisen product γ,δ-unsaturated acid need to activated for the 
successive alkylation/acylation. The alkylation product could converted to ketene acetal in 
presence of base and followed by the rearrangement to complete the iterative process. In proposed 
iterative Claisen rearrangement, the Claisen product benzothiazole derivative readily available for 
the successive alkylation, which will converted to ketene acetal and followed by the rearrangement 
to complete the process. This ideology prompted us to testify the advantage of the benzothiazole 
based iterative Claisen rearrangement.  
The successive alkylation of the Claisen rearrangement products not listed in the literature 
and the reasons for those alkylation attempts were unclear. In this proposed Claisen rearrangement, 
the ketene acetal formation from benzothiazolium salt with basic condition was necessary. The 
parent benzothiazole Claisen rearrangement product 13.2 has two α- hydrogens (to benzothiazole 
moiety), which might lead to successive ketene acetal formation for the iterative synthesis. To 
explore the available options, we started the alkylation of Claisen product 13.2 with allyl tosylate, 
which gave the benzothiazolium salt 31.1 in 76% yield. The benzothiazolium salt was treated with 
the previous developed conditions successfully resulted in iterative Claisen product 31.3 with 80% 
yield. The intermediate ketene acetal formation 31.2 tracked through the NMR spectroscopy. The 
iterative Claisen product 31.3 still had the α-hydrogen to allow a similar reaction. The iterative 
benzothiazole Claisen product 31.3 alkylated with allyl tosylate, which successfully gave the 
benzothiazolium salts 31.4 in 81% yield. The steric hindered benzothiazolium salt 31.4 treated 
with TMG base for the ketene acetal formation 31.5 and confirmed through the NMR 
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spectroscopy. As per computational studies, the Claisen rearrangement should happen at the lower 
temperature than the reported reaction temperature of 180 0C. The crude ketene acetal 31.5 heated 
at 80 0C, which successfully produced the iterative Claisen product 31.6 in 88% yield (Scheme 
36). At explored reaction heating conditions starting from the room temperature to 60 0C, the 
Claisen product did not formed.  
 





According to the transition states, (Z)-N-allyl ketene acetal 31.2 was favorable than the 
(E)-N-allyl ketene acetal due the nonbonding interactions. The iterative Claisen product 31.3 was 
formed through both chair and boat confirmation of the (Z)-N-allyl ketene acetal 31.2. The non-
bonding interaction due to steric C-2 substitution in N-allyl ketene acetal 31.5 clearly disfavored 
the both chair and boat transition states for the corresponding iterative Claisen product 31.6 
(Scheme 37). Despite of these unfavorable conditions the iterative Claisen product 31.6 reported 
at much lower temperature than the traditional high heating temperatures. 
As per computational studies, we believe that the N-C bond in the N-allyl ketene acetal 
31.5 bent due to the steric C-2 substitution on the N-allyl ketene acetal, which resembles the 
transition state of the conceding Claisen rearrangement.  
 
 
Scheme 37: Transition states of iterative Claisen rearrangement 
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4. Preparation of pentenoic acid derivatives through benzothiazole cleavage  
 
            Benzothiazole derivatives can serve as carboxylic acid surrogates and many methods were 
available for their successful transformation. To demonstrate the alternative approach for the 
Ireland-Claisen rearrangement as our proposed benzothiazole based Claisen rearrangement, we 
need to achieve acid derivatives through cleavage of the benzothiazole derivatives, which were 
readily available from Claisen rearrangement. As per literature Dondoni et al, have reported few 
methods for the synthesis of acids and/or aldehyde derivatives by hydrolysis of benzothiazole 
moiety24. The benzothiazole hydrolysis typically begins with the alkylation of the benzothiazole 
33.1 with strong alkylating agents such as methyl triflate or a large excess of methyl iodide to 
afford the activated benzothiazolium salt 33.2. The benzothiazolium salt is reduced with sodium 
borohydride and this was followed by hydrolysis methodology with mercury, silver and copper to 
provide the acid and/or aldehyde derivatives 33.425, 26 (Scheme 38).  
 
Scheme 38: Scheme of benzothiazole cleavage 
 
68 
            Our studies commenced with alkylation of benzothiazole derivative 13.2 with excess 
methyl iodide, which resulted the activated N-methyl benzothiazolium salt 34.1 in good yields.  In 
literature, the hydrazine’s react with the carbonyl compounds and its equivalents to synthesize 
various organic compounds27, 28 and 29. The N-methyl benzothiazolium salt treated with hydrazine 
to synthesize corresponding acid derivative but gave unsuccessful results. The reaction conditions 
were encouraging with the cleavage of the benzothiazole ring that formed the 2-thiomethylaniline 
34.2 with unidentified product. At this stage, we believed that the desired acid derivative 34.3 was 
not identified and isolated might account of low molecular weight and/or high volatility of the 
compound (Scheme 39). 
 
          
Scheme 39: Proposed benzothiazole hydrogenolysis reaction 
We further employed the higher molecular weight 2-(2-phenylbut-3-enyl) benzothiazole 
compound 20.1.  The benzothiazole derivative methylated with excess methyl iodide and delivered 
the N-methyl benzothiazolium salt 35.1 in excellent yield.  The N-methyl benzothiazolium salt 
treated with hydrazine to produce acid derivative. Clearly, the hydrogenolysis of the N-methyl 
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benzothiazolium salt with the hydrazine derivative yielded the undesired 2-thiomethylaniline 34.2 
with no sign of the desired product (acid derivative) (Scheme 40). With compilation of 
spectroscopic methods, we assumed that the unsaturation (double bond) of the substituted part of 




Scheme 40: Hydrogenolysis attempt with benzothiazolium salts. 
           
         The investigation started with switching the counter ion in the N-methyl benzothiazolium 
iodide salt 35.1. The ion exchange of the iodine counter ion with the tosylate counter ion by simply 
triturating the benzothiazolium iodide salt 35.1 with the silver tosylate in presence of methanol 
yielded the insoluble silver iodide and benzothiazolium tosylate salt 36.1. The benzothiazolium 
salt with the tosylate counter ion was proceeded with the hydrogenolysis conditions to cleave the 
benzothiazolium salt resulted in formation of 2-thiomethylaniline with unidentified product. This 





Scheme 41: Ion exchange reaction of benzothiazolium salts 
 
                   The investigation continued with the saturation of terminal alkene in benzothiazole 
derivative. The benzothiazole derivative 20.1 successfully saturated by hydrogen gas and Pd/C 
metal to provide the desired product 37.1. The saturated benzothiazole derivative 37.1 alkylated 
with methyl iodide producing N-methyl benzothiazolium salt 37.2 in good yield.  The N-methyl 
benzothiazolium salt 37.2 was treated with hydrazine to cleave the benzothiazolium salt resulted 
in formation of 2-thiomethylaniline with unidentified product. The results of exploring saturated 
benzothiazole derivative for the hydrogenolysis did not have any impact on the outcome of the 
reaction.  All of our hydrogenolysis experimental studies gave successful results of hydrolysis of 
the benzothiazole ring, but we ended up with separating the aromatic part of 2-thiomethylaniline 





Scheme 42: Hydrogenolysis attempts of benzothiazolium salts with hydrazine 
 
              At this stage, we used hydrazine and hydrazine monohydrate as nucleophile to cleave the 
benzothiazolium salts for the synthesis of corresponding acid derivative. We decided to explore 
the possible amine derivatives as a reagent for the benzothiazole hydrogenolysis. The 
commercially available amine derivatives such as N, O-dimethyl hydroxylamine 38.1, phenyl 
hydrazine 38.2, phenyl hydrazine hydrochloride 38.3, tert-butyl carbazide 38.4, tosyl hydrazine 
38.5, piperidine 38.6 and pyrrolidine 38.7 tested with hydrogenolysis conditions. All of these 
reaction attempts with the amine derivatives and the N-methyl benzothiazolium salts resulted in 
the starting material recovery. The solvent combination of water and methanol with temperature 
adjustments did not make any impact on the product formation. Finally, hydrazine and hydrazine 
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monohydrate successfully cleaved the benzothiazole ring producing only the aromatized product 
2-thiomethylaniline 34.2 with unidentified products. At same time, not all other amine derivatives 
have made any impact to cleave the benzothiazole ring (Scheme 43). 
  
 
Scheme 43: Hydrogenolysis attempts of benzothiazolium salts with various nucleophiles 
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III. Future studies: 
 The Claisen rearrangement under milder conditions were successfully developed and 
demonstrated the functional group (unprotected alcohols, aldehydes, amides, ester and ethers) 
compatibility. This methodology of Claisen rearrangement was established and studied with 
heterocycle benzothiazole and various allyl bromide derivatives. We want to expand our 
methodology for other feasible heterocycle compounds such as thiazoline and many more. The 
proposed methodology for the future work shown below in Scheme 44. 
 
 
Scheme 44: Proposed Claisen rearrangement with 2-methyl thiazoline  
 
  The demonstrated Claisen rearrangement methodology was limited to racemic synthesis 
and we are planning to demonstrate the asymmetric synthesis of the Claisen rearrangement by 
gaining the advantage of catalyzing reaction conditions (Scheme 45). 
 
 
Scheme 45: Proposed asymmetric Claisen rearrangement 
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VI. Experimental section and spectral data: 
General Information  
All reactions conducted under an inert atmosphere using standard conditions. Apart from this, no 
other precise attempt made to exclude air or moisture. The commercially available reagents used 
without additional purification unless otherwise indicated. Compound purification effected by 
flash chromatography using 230x400 mesh, 60 Å porosity obtained from Sorbent Technologies, 
Yamazen smart flash automatic chromatography and by recrystallization from indicated solvents. 
Melting points taken using a Stuart SMP 10 and a Fisher-Johns melting point apparatuses. Proton 
and Carbon NMR spectra obtained on availability of 300, 400 and 700 MHz Bruker Avance 
spectrometer. Structural assignments based on 1H, 13C, and IR spectroscopies. Elemental analyses 
performed by Atlantic Micro lab, Inc.  
 
Cinnamyl bromide. This compound is commercially available; however, it is very expensive. In 
the literature, there is only one procedure proposed by Zhang et al to prepare such compound 
starting from cinnamyl chloride and using Rhodium as a catalyst.16 It was prepared here in a new 
and convenient way (Finkelstein variation on Wagner reaction).17 
A mixture of cinnamyl chloride (3 mL, 21.5 mmol) and sodium bromide (6.65 g, 6.46 mmol) in 
acetone (15 mL) heated under reflux for 4 days. The reaction then filtered to remove solids and 
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the filtrate was concentrated in vacuo to produce cinnamyl bromide (3.87 g, 91%) as a light brown 
oil. Analytical data matched a commercial sample.16 
 
A mixture of (Z) 4-chloro-2-butenol (3 mL, 21.5 mmol) and sodium bromide (6.65 g, 6.46 mmol) 
in acetone (15 mL) was heated under reflux for 4 days. The reaction then was filtered to remove 
solids and the filtrate was concentrated in vacuo to produce (Z)-4-Bromobut-2-en-1-ol (3.87 g, 
91%) as a light brown oil. Analytical data matched a reported sample.18 
 
 
Myrtenyl bromide made from a reported procedure. Phosphorus tribromide (0.32 ml, 3.4 mmol) 
was added to a cooled solution of Myrtenol (0.8 ml, 5 mmol) in diethyl ether (7 ml) and was stirred 
at 0 oC for 1.5 hours. Reaction was quenched with saturated NaHCO3 and organic product 
extracted into ether. Organic layer was dried with MgSO4, filtered and solvent evaporated in-vacuo 





To a stirred solution of 2-hydroxy benzothiazole (500 mg, 33 mmol) and K2CO3 (502 mg, 36 
mmol) in dry acetonitrile was added to (E)-1,4- dibromo-2-butene (778 mg, 36 mmol) in single 
portion. The reaction mixture heated to reflux for 4 hours and monitor the reaction through the 
TLC for completion of reaction. Then the reaction mixture was cooled to room temperature (rt) 
and filtered to remove the insoluble residues. The solvent was removed under reduced pressure to 
collect the crude reaction mixture and column purification (eluent: 98:02 to 95:05 
Hexanes/EtOAc) was performed to yield the (404 mg, 43%) pure product as white powder. M.P 
87- 88 0C.  1H NMR (400 MHz, CDCl3) 3.91 (d, J= 6.7 Hz, 2H), 4.59 (d, J=6.9 Hz, 2H), 5.82 - 
5.98 (m, J=7.7 Hz, 2H), 7.01 (t, J=7.4 Hz, 1H), 7.12 (t, J=7.5 Hz, 1H), 7.35 (d, J=7.9 Hz, 1H), 
7.48 (d, J=8.1 Hz, 1H);  13C NMR (400 MHz, CDCl3) 29.72, 31.05, 43.41, 110.95, 122.71, 123.36, 
126.44, 127.68, 129.96, 136.70, 169. IR (thin film) ν max: 2924, 2850, 1658, 1589, 1469, 1315, 
1303, 1188, 774, 621 cm -1. Elemental Analysis: calcd for C11H10NOSBr: C 46.64 H, 3.53 N 4.94 
S 11.30 Br 28.23, found C 47.23 H, 3.68 N 4.83 S 11.32 Br 28.94. 
 
 
To a stirred solution of 4-acetamidophenol (1.00 g, 66 mmol) and K2CO3 (1.00 g, 72 mmol) in dry 
acetonitrile was added to (E)-1,4- dibromo-2-butene (1.56 g, 72 mmol) in single portion. The 
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reaction mixture heated to reflux for 4 hours and monitor the reaction through the TLC for the 
completion of reaction. Then the reaction mixture was cooled to room temperature (rt) and filtered 
to remove the insoluble residues. The solvent was removed under reduced pressure to collect the 
crude reaction mixture and column purification (eluent: 98:02 to 90:10 Hexanes/EtOAc) was 
performed to yield the (0.99 g, 71%) pure product as white solid.  M.P 126- 129 0C;  1H NMR (400 
MHz, CDCl3) 2.15 (s, CH3, 3H), 3.99 (d, J= 7.1 Hz, 2H), 4.53 (d, J=5.6 Hz, 2H), 5.85 - 5.98 (m, 
J=7.6 Hz, 2H), 6.06 (td, J= 7.4 Hz, 7.1 Hz 2H), 6.85 (td, J= 7.7 Hz, 5.1Hz 2H), 6.85 (d, J=8.9 Hz, 
2H), 7.12 (bs, NH,  1H), 7.39 (d, J=8.9 Hz, 2H),);  13C NMR (400 MHz, CDCl3) 24.39, 31.60, 
67.53, 115.05, 121.84, 129.26, 130.04, 131.30, 155.21, 168.14. IR (thin film) ν max: 3317, 2924, 
1654, 1616, 1521, 1462, 1408, 1373, 1315, 1300, 1246, 1215, 1010, 968, 825, 717, 601 cm -1. 
Elemental Analysis: calcd for C12H13NO2Br: C 50.87 H, 4.59 N 4.69 Br 23.23, found C 52.83 H, 
5.30 N 5.03 Br 23.31. 
 
 
To a stirred solution of vanillin (1.00 g, 65 mmol) and K2CO3 (1.02 g, 72 mmol) in dry acetonitrile 
was added to (E)-1,4- dibromo-2-butene (1.54 g, 72 mmol) in single portion. The reaction mixture 
heated to reflux for 4 hours and monitor the reaction through the TLC for completion of the 
reaction. Then the reaction mixture was cooled to room temperature (rt) and filtered to remove the 
insoluble residues. The solvent was removed under reduced pressure to collect the crude reaction 
mixture and column purification (eluent: 98:02 to 90:10 Hexanes/EtOAc) was performed to yield 
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the (0.82 g, 57%) pure product as white solid. M.P 66 - 68 0C; 1H NMR (400 MHz, CDCl3) 3.97 
(s, CH3, 3H), 3.99 (d, J=7.2 Hz, 2H), 4.69 (d, J=4.9 Hz, 2H), 6.06 (ddd, J=13.3, 7.1, 4.9 Hz, 1H), 
6.08 (ddd, J=13.3, 7.1, 6.9 Hz, 1H), 7.01 (d, J=8.2 Hz, 1H), 7.45 (d, J=1.6 Hz, 1H), 7.49 (dd, 
J=8.1, 1.7 Hz, 1H), 9.86 (s, CHO, 1H);  13C NMR (400 MHz, CDCl3) 31.37, 56.21, 68.24, 110.78, 
127.05, 129.22, 130.16, 148.35, 154.85, 190.77. IR (thin film) ν max: 2846, 1676, 1666, 1597, 1508, 
1431, 1388, 1261, 1246, 1230, 1211, 1192, 1161, 1134, 1018, 972, 825, 810, 640 cm -1. Elemental 
Analysis: calcd for C12H13O3Br: C 50.70 H, 4.57 Br 28.13, found C 50.31 H, 4.73 Br 28.18. 
  
 
To a mixture of NaH (60% oil in suspension) (0.151 g, 63 mmol) in dry THF, the diethyl methyl 
malonate (1.00 g, 57 mmol) was added at 0 0C and the reaction mixture was stirred at room 
temperature for 1 hour. (E)-1,4- dibromo-2-butene (1.35 g, 63 mmol) was added to reaction 
mixture and the mixture was heated to reflux overnight. After completion of the reaction, the 
reaction mixture quenched with 1 M HCl, the crude product was extracted with ether, and the 
organic layer was separated. The organic layer washed with water and dried on Na2SO4. The 
solvent was removed under reduced pressure to collect the crude reaction mixture and column 
purification (eluent: 98:02 to 95:05 Hexanes/EtOAc) was performed to yield the (1.21 g, 69%) 
pure product as color less oil.  1H NMR (400 MHz, CDCl3) 1.21 (t, J= 7.2 Hz, 6H), 1.39 (s, CH3, 
3H), 2.61 (d, J=6.2 Hz, 2H), 3.89 (d, J=6.6 Hz, 2H), 4.35 (q, J=7.2 Hz, 4H), 5.77 - 5.82 (m, J=7.6 
Hz, 2H);  13C NMR (400 MHz, CDCl3) 14.06, 19.88, 32.34, 38.31, 53.51, 61.36, 130.00, 130.64, 
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171.65.  IR (thin film) ν max: 2924, 2850, 1658, 1589, 1469, 1435, 1369, 1357, 1141, 1095, 1080, 
1060, 975, 952, 933, 744, 621 cm -1. Elemental Analysis: calcd for C12H19O4Br: C 47.05 H, 6.20 
Br 26.10, found C 47.11 H, 6.26 Br 26.27. 
 
General produced for the Claisen rearrangement products. TMG (1.1 eq) was added to a 
suspension of N-allyl-2-methylbenzothiazolium tosylate (1 eq) in toluene (20 mL for 1 mmol) at 
room temperature. After stirring at that temperature for 15 min, the reaction mixture filtered 
through a Celite® filter fritted funnel and rinsed with toluene (5-10 mL). The filtrate transferred 
to a pressure vessel, immersed in a pre-heated oil bath at 180 oC and stirred at 170-175 oC for 1 
hour. Concentration in vacuo gave the title crude compound and purified by column 
chromatography as hexanes and ethyl acetate as solvent system. 
 
 
Obtained as a light brown oil with 71% yield.  1H NMR (400 MHz, CDCl3) 2.64 (app quartet, 
J=7.4 Hz, 2H), 3.22 (t, J=7.8 Hz, 2H), 5.06 (d, J=10.2 Hz, 1H), 5.14 (d, J=17.1 Hz, 1H), 5.9 
(ddt, J=16.9, 10.3, 6.5 Hz, 1H), 7.35 (t, J=7.5 Hz, 1H), 7.44 (t, J=7.5 Hz, 1H), 7.84 (d, J=7.8 Hz, 
1H), 7.98 (d, J=8.0 Hz, 1H);  13C NMR (400 MHz, CDCl3) 33.38, 33.73, 116.21, 121.50, 122.59, 




Eluent: 97:03 to 90:10 Hexanes/EtOAc; Obtained as a dark brown oil with 68% yield.  1H NMR 
(400 MHz, CDCl3)   3.03 (t, J=7.5 Hz, 2H), 3.39 (t, J=7.5 Hz, 2H), 5.48 (S, 1H), 5.67 (S, 1H), 
7.37 (t, J=7.5 Hz, 1H), 7.47 (t, J=7.6 Hz, 1H), 7.85 (d, J=7.9 Hz, 1H), 7.98 (d, J=8.0 Hz, 1H); `13C 
NMR (400 MHz, CDCl3) 32.89, 40.80, 118.36, 121.54, 122.66, 124.90, 126.02, 131.83, 135.14, 
153.21, 169.37. IR (thin film) ν max: 2962, 2924, 2870, 1643, 1589, 1558, 1512, 1458, 1365, 1311, 
1242, 1180, 1157, 1095, 1064, 1002, 910, 859, 810, 756, 725 cm -1. Elemental Analysis: calcd for 




Eluent: 97:03 to 90:10 Hexanes/EtOAc; Obtained as a brown oil with 61% yield.  1H NMR (400 
MHz, CDCl3) 1.82 (S, CH3, 3H), 2.60 (t, J=7.9 Hz, 2H), 3.28 (t, J=7.8 Hz, 2H), 4.80 (s, 2H), 7.35 
(t, J=7.1 Hz, 1H), 7.44 (t, J=7.1 Hz, 1H), 7.84 (d, J=7.9 Hz, 1H), 7.97 (d, J=8.0 Hz, 1H); `13C 
NMR (400 MHz, CDCl3) 22.51, 32.71, 37.24, 111.26, 121.50, 122.55, 124.69, 125.90, 135.15, 
143.76, 153.22, 171.53. IR (thin film) ν max: 3070, 2962, 2924, 2846, 1782, 1651, 1558, 1519, 
1435, 1311, 1280, 1111, 1064, 887, 779, 725 cm -1. Elemental Analysis: calcd for C12H13NS: C 
70.90 H, 6.4 N 6.89 S 15.75, found C 71.04 H, 6.63 N 6.91 S 15.77. 
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Eluent: 97:03 to 90:10 Hexanes/EtOAc; Obtained as a color less oil with 42% yield.  1H NMR 
(400 MHz, CDCl3) 1.18 (S, CH3, 6H), 3.13 (S, 2H), 5.01 (d, J=10.3 Hz, 1H), 5.04 (d, J=17.1 Hz, 
1H), 5.98 (dd, J=17.1, 10.7 Hz, 1H), 7.36 (t, J=7.1 Hz, 1H), 7.45 (t, J=7.2 Hz, 1H), 7.83 (d, J=7.8 
Hz, 1H), 8.00 (d, J=8.0 Hz, 1H); `13C NMR (400 MHz, CDCl3) 26.88, 37.66, 47.02, 112.12, 
121.29, 122.66, 124.69, 125.76, 135.59, 146.670, 146.677, 152.98, 168.43. IR (thin film) ν max: 
3078, 2958, 2912, 1512, 1458, 1414, 1383, 1315, 1276, 1242, 1172, 1153, 1091, 1060, 1010, 999, 
914, 887, 856, 833, 756, 709 cm -1. Elemental Analysis: calcd for C13H15NS: C 71.85 H, 6.90 N 
6.44 S 14.74, found C 72.06 H, 7.06 N 6.27 S 14.47. 
 
 
Eluent: 97:03 to 90:10 Hexanes/EtOAc; Obtained as a brown oil with 45% yield.  1H NMR (400 
MHz, CDCl3) 1.77 (S, CH3, 3H), 1.48 (dd, J= 8.5, 4.8Hz, 2H), 1.62 (s, CH3, 3H), 1.69 (s, CH3, 
3H), 2.05 (dt, J=16.4, 7.3 Hz 2H), 3.20 (t, J=7.7 Hz, 2H), 5.04 (d, J=10.3 Hz, 1H), 5.09 (d, J=17.1 
Hz, 1H), 5.93 (dd, J= 10.3, 8.7 Hz, 1H), 7.36 (d, J=7.5 Hz, 2H), 7.46 (t, J=7.1 Hz, 1H), 7.84 (d, 
J=7.9 Hz, 1H), 8.01 (d, J=8.2 Hz, 1H); `13C NMR (400 MHz, CDCl3) 17.66, 22.66, 22.97, 25.70, 
40.83, 45.69, 109.98, 113.58, 121.26, 122.65, 124.66, 125.72, 131.50, 135.63, 154.29, 152.93, 
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168.27. IR (thin film) ν max: 3068, 2962, 2912, 1508, 1454, 1411, 1373, 1311, 1276, 1242, 1153, 
1091, 1060, 999, 914, 887, 833, 756, 729 cm -1. Elemental Analysis: calcd for C18H23NS: C 75.74 
H, 8.06 N 4.90 S 11.22, found C 75.99 H, 8.11 N 4.88 S 10.96. 
 
 
Eluent: 98:02 to 90:10 Hexanes/EtOAc; Obtained as a light brown oil with 76% yield.  1H NMR 
(400 MHz, CDCl3) 3.5 (m, J=7.5 Hz, 1H), 3.55 (m, J=7.5 Hz, 1H), 4.0 (app quartet, J=7.4 Hz, 
1H), 5.09 (d, J=11.4 Hz, 1H), 5.1 (d, J=16.1 Hz, 1H), 6.1 (ddd, J=17.3, 10.1, 7.2 Hz, 1H), 7.22 (t, 
J=6.9 Hz, 1H), 7.30 (m, J=6.7 Hz, 5H), 7.44 (t, J=8.0 Hz, 1H), 7.79 (d, J=7.9 Hz, 1H), 7.98 (d, 
J=8.1 Hz, 1H); `13C NMR (400 MHz, CDCl3) 40.17, 49.70, 115.68, 121.477, 122.62, 124.72, 
125.86, 126.85, 127.75, 128.70, 135.27, 140.112, 142.27, 153.07, 169.69. IR (thin film) ν max: 
3061, 3025, 2981, 1712, 1516, 1435, 1126, 917, 728, 669 cm -1. Elemental Analysis: calcd for 
C17H15NS: C 76.95 H, 5.65 N 5.28 S 12.07, found C 76.88 H, 5.54 N 5.28 S 12.15. 
 
 
Eluent: 90:10 to 75:25 Hexanes/EtOAc; Obtained as a light brown oil with 54% yield.  1H NMR 
(400 MHz, CDCl3) 2.49 (s, OH, 1H), 2.89 (m, J=6.7 Hz, 1H), 3.27 (dd, J=7.8 Hz, 2H), 3.68 (s, 
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2H), 5.14 (d, J=10.1 Hz, 1H), 5.19 (d, J=17.1 Hz, 1H), 5.81 (ddd, J=17.1, 10.3, 8.4 Hz, 1H), 7.37 
(t, J=7.4 Hz, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.99 (d, J=8.0 Hz, 1H); `13C 
NMR (400 MHz, CDCl3) 35.76, 46.02, 64.91, 117.65, 121.50, 122.60, 124.90, 126.03, 137.73, 
153.06, 169.66. IR (thin film) ν max: 3336 (bs), 3070, 2920, 2866, 1639, 1512, 1454, 1419, 1369, 
1334, 1311, 1280, 1246, 1153, 1103, 1053, 1014, 991, 918, 729, 705 cm -1. Elemental Analysis: 
calcd for C12H13NOS: C 75.73 H, 5.93 N 6.29 S 14.60, found C 64.62 H, 6.38 N 6.11 S 13.74. 
 
 
Eluent: 97:03 to 90:10 Hexanes/EtOAc; M.P 58 - 59 0C Obtained as a light green solid with 58% 
yield.  1H NMR (400 MHz, CDCl3)  0.78(S, CH3, 3H), 1.27 (S,CH3, 3H), 1.29 (d, J= 10 Hz, 1H), 
1.78 ( dt, J=13.9 Hz, 2.8 - 3.2 Hz, 1H), 2.02 (dd, J=8.7, 5.5 Hz, 1H), 2.10 (dt, J=11.9, 1.6 Hz, 1H), 
2.42 (app quartet, J=8.1, 5.5 Hz, 1H), 2.55 (t, J=7.5 Hz, 1H), 3.22 (dt, J=9.3, 8.7 Hz, 1H), 3.28 
(dd, J= 14.49, 11 Hz, 1H), 3.49(dd, , J=14.5, 5.6 Hz, 1H), 4.83 (d, J=24.15 Hz, 2H), 7.39 (t, J=7.5 
Hz, 1H), 7.49 (t, J=7.6 Hz, 1H), 7.87 (d, J=7.9 Hz, 1H), 8.02 (d, J=8.1 Hz, 1H); `13C NMR (400 
MHz, CDCl3) 21.76, 25.80, 28.60, 30.21, 35.05, 40.21, 40.89, 46.70, 52.24, 109.02, 121.55, 
122.61, 124.81, 125.97, 135.16, 153.09, 154.61, 171.20. IR (thin film) ν max: 3042, 2962, 2908, 
2866, 1635, 1516, 1454, 1435, 1257, 1246, 1114, 1095, 1064, 1041, 1014, 887, 798, 759 cm -1. 
Elemental Analysis: calcd for C18H21NS: C 76.28 H, 7.41 N 4.94 S 11.30, found C 76.02 H, 7.55 




Eluent: 97:03 to 90:10 Hexanes/EtOAc; M.P 90 - 91 0C. Obtained as a pale yellow solid with 53% 
yield.  1H NMR (400 MHz, CDCl3) 3.31 (dd, , J=7.4 Hz, 2H), 3.43 (m, J=7.2 Hz, 1H), 4.13 (ddd, 
J=11.6, 8.7 Hz, 2H), 5.01 (d, J=10.6 Hz, 1H), 5.07 (d, J=17.2 Hz, 1H), 5.84 (ddd, J=17.2, 9.9, 7.2 
Hz, 1H), 7.19 (t, J=7.6 Hz, 1H), 7.23 (t, J=7.9 Hz, 1H), 7.35 (t, J=6.1 Hz, 1H), 7.40 (d, J=7.8 Hz, 
1H), 7.41 (d, J=7.7 Hz, 1H), 7.50 (t, J=8.1 Hz, 1H), 7.87 (d, J=7.9 Hz, 1H), 7.99 (d, J=7.9 Hz, 
1H); `13C NMR (400 MHz, CDCl3) 37.09, 42.43, 46.21, 111.12, 118.56, 121.55, 122.57, 122.64, 
123.11, 124.98, 126.04, 126.33, 136.96, 153.17, 155.57, 168.13. IR (thin film) ν max: 3070, 2938, 
2866, 1678, 1651, 1585, 1473, 1435, 1330, 1149, 914, 748, 729, 709, 671 cm -1. Elemental 




Eluent: 80:10 to 65:35 Hexanes/EtOAc; Obtained as a thick yellow oil with 47% yield.  1H NMR 
(400 MHz, CDCl3) 2.15 (s, CH3, 3H), 3.28 (dd, J=14.1, 6.3 Hz, 2H), 3.48 (dd, J=8.4, 5.7 Hz, 1H), 
4.01 (t, J=11.3 Hz 2H), 5.16 (d, J=10.4 Hz, 1H), 5.21 (d, J=17.5 Hz, 1H), 5.93 (ddd, J=16.5, 9.7, 
7.7 Hz, 1H), 6.86 (d, J=8.5 Hz, 1H), 7.31 (t, J=7.3 Hz, 1H), 7.39 (t, J=7.7 Hz, 1H),  7.46 (t, J=7.7 
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Hz, 1H), 7.85 (d, J=7.8 Hz, 1H), 7.99 (d, J=8.0 Hz, 1H); `13C NMR (400 MHz, CDCl3) 24.32, 
35.98, 43.66, 70.27, 114.93, 117.59, 121.51, 121.85, 122.60, 124.81, 125.94, 131.28, 137.12, 
153.17, 155.57, 168.13, 169.53. IR (thin film) ν max: 3278, 3251, 3190, 3132, 3066, 2920, 1654, 
1600, 1543, 1504, 1465, 1435, 1411, 1311, 1269, 1172, 1114, 1037, 1014, 968, 3070, 2938, 2866, 
1678, 1651, 1585, 1473, 1435, 1330, 1234, 1149, 914, 729, 709, 671 cm -1. Elemental Analysis: 
calcd for C20H20N2O2S: C 68.15 H, 5.67 N 7.95 S 9.08, found C 66.50 H, 6.31 N 7.39 S 6.47. 
 
 
Eluent: 80:10 to 65:35 Hexanes/EtOAc; Obtained as a light brown viscous oil with 67% yield.  1H 
NMR (400 MHz, CDCl3) 3.34 (app quartet, J=8.1 Hz, 2H), 3.54 (t, J=8.9 Hz, 2H), 4.15 (m, J= 8.9 
Hz, 2H), 5.20 (d, J=14.6 Hz, 1H), 5.24 (d, J=21.6 Hz, 1H), 5.96 (ddd, J=17.1, 10.3, 9.6 Hz, 1H), 
6.97(d, J=8.3 Hz, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.44 (d, J=9.5 Hz, 2H), 7.46 (d, J=9.5 Hz, 1H), 7.85 
(d, J=8.1 Hz, 1H), 8.01 (d, J=8.3 Hz, 1H), 9.83 (s, 1H); `13C NMR (400 MHz, CDCl3) 36.19, 43.39, 
56.04, 71.28, 110.80, 111.25, 117.84, 121.46, 122.68, 124.76, 125.91, 126.90, 135.32, 136.82, 
148.82, 153.24, 155.11, 169.40, 190.84.  IR (thin film) ν max: 3084, 2973, 2846, 1666, 1639, 1567, 
1508, 1431, 1388, 1261, 1230, 1211, 1192, 1161, 1134, 1018, 972, 825, 756 cm -1. Elemental 




Eluent: 97:03 to 90:10 Hexanes/EtOAc; Obtained as a white semi solid with 72% yield.  1H NMR 
(400 MHz, CDCl3) 1.18 (t, J=6.1Hz, 3H), 1.23 (t, J=4.8Hz, 3H), 1.45 (s, CH3, 3H), 2.16 (ddd, 
J=12.0 Hz, 9.9 Hz, 6.0 Hz 2H), 2.84 (m, J=11.1 Hz, 1H), 3.13 (ddd, J=18.0 Hz, 9.0 Hz, 6.5 Hz 
2H), 4.17 (q, J=10.7 Hz, 4H), 4.94 (d, J=9.9 Hz, 1H), 4.96 (d, J=17.1 Hz, 1H),  5.58 (ddd, J=17.1 
Hz, 9.6 Hz, 7.6 Hz, 1H), 7.34 (t, J=7.5 Hz, 1H), 7.44 (t, J=7.7 Hz, 1H), 7.82 (d, J=7.9 Hz, 1H), 
7.96 (d, J=8.1 Hz, 1H); 13C NMR (400 MHz, CDCl3) 13.90, 13.95, 20.01, 39.33, 41.06, 41.27, 
53.03, 61.05, 61.35, 116.74, 121.46, 122.68, 124.76, 125.87, 135.28, 139.88, 153.14, 169.39, 
171.73, 172.35. IR (thin film) ν max: 3074, 2978, 2920, 1639, 1512, 1454, 1435, 1365, 1311, 1276, 
1246, 1168, 1095, 1060, 991, 914, 756, 729 cm -1. Elemental Analysis: calcd for C20H25NO4S: C 
63.97 H, 6.66 N 3.73 S 8.52, found C 62.86 H, 6.82 N 3.58 S 8.15. 
 
 
Eluent: 97:03 to 90:10 Hexanes/EtOAc; Obtained as a dark brown oil with 80% yield.  1H NMR 
(400 MHz, CDCl3)  2.61 (dd, J=7.52 Hz, 4H), 3.51 (t, J=6.7 Hz, 1H), 5.02 (d, J=10.0 Hz, 2H), 
5.08 (d, J=17.0 Hz, 2H), 5.81 (ddt, J=17.9, 10.0, 7.2 Hz, 2H), 7.36 (t, J=6.7 Hz, 1H), 7.45 (t, J=7.0 
Hz, 1H), 7.85 (d, J=7.4 Hz, 1H), 7.99 (d, J=7.7 Hz, 1H); `13C NMR (400 MHz, CDCl3) 39.37, 
87 
44.66, 117.44, 121.55, 122.75, 124.68, 125.82, 135.15, 153.04, 175.08. IR (thin film) ν max: 3074, 
2978, 2920, 1639, 1504, 1435, 1415, 1330, 1311, 1280, 1242, 1176, 1153, 1126, 1087, 1056, 995, 
968, 858, 756, 729 cm -1. Elemental Analysis: calcd for C14H15NS: C 73.33 H, 6.54 N 6.11 S 13.96, 




Eluent: 98:02 to 90:10 Hexanes/EtOAc; Obtained as a dark brown oil with 88% yield.  1H NMR 
(400 MHz, CDCl3)  2.66 (d, J=7.1 Hz, 6H), 5.09 (t, J=10.3 Hz, 6H), 5.71 (ddt, J=16.3, 9.2, 7.5 Hz, 
3H), 7.36 (t, J=7.4 Hz, 1H), 7.46 (t, J=7.5 Hz, 1H), 7.87 (d, J=7.8 Hz, 1H), 8.02 (d, J=8.0 Hz, 1H); 
`13C NMR (400 MHz, CDCl3) 42.28, 47.61, 118.69, 121.44, 122.93, 124.66, 125.72, 133.20, 
134.89, 152.91, 178.07. IR (thin film) ν max: 3061, 2981, 1735, 1712, 1516, 1473, 1458, 1430, 
1373, 1365, 1265, 1222, 1165, 1107, 1087, 1018, 921, 864, 771, 655 cm -1. Elemental Analysis: 
calcd for C17H19NS: C 75.80 H, 7.06 N 5.20 S 11.89, found C 76.05 H, 7.11 N 5.16 S 11.65. 
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General produced for the benzothiazolium salts: 2-Methylbenzothiazole (1 eq) and allyl 
bromide derivatives (1.1 - 1.2 eq) were placed in a pressure vessel at room temperature. The 
mixture stirred and heated to 120 oC for a total of 1 hour. The resulting oil allowed cooling down 
to room temperature. Diethyl ether (10 mL) added and vigorously stirred at room temperature until 
a solid precipitate formed. Subsequent filtration yielded salt and salt washed with excess diethyl 
ether.   
 
1H NMR (400 MHz, CDCl3) 2.27 (s, 3H), 3.29 (s, 3H), 5.02 (d, J=17.2 Hz, 1H), 5.32 (d, J=10.5 
Hz, 1H), 5.53 (d, J=5.1 Hz, 2H), 5.98 (ddt, J=17.2, 10.5, 5.1 Hz, 1H), 7.01 (d, J=8.2 Hz, 2H), 
7.60 (d, J=8.2 Hz, 2H), 7.64 (t, J=7.8 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 7.90 (d, J=8.4 Hz, 1H), 
8.15 (d, J=8.0 Hz, 1H); 13C NMR (400 MHz, CDCl3) 17.45, 21.20, 51.92, 116.65, 119.88, 
124.32, 125.75, 128.32, 128.40, 129.00, 129.70, 138.89, 140.86, 143.95, 176.78; Data matched 





M.P 172- 174 0C;  1H NMR (400 MHz, CDCl3) 3.56 (s, 3H), 5.94 (d, J=2.5 Hz, 1H), 6.11 (s, 2H), 
6.63 (s, 1H), 7.70 (t, J=7.7 Hz, 1H), 7.81 (t, J=7.9 Hz, 1H), 8.21 (d, J=8.5 Hz, 1H), 8.31 (d, J=8.1 
Hz, 1H); 13C NMR (400 MHz, CDCl3) 20.55, 55.70, 113.40, 116.78, 124.49, 128.68, 129.99, 
138.41, 142.40, 177.37. IR (thin film) ν max: 3410, 3375, 3363, 2924, 2360, 2337, 1465, 1450, 
1419, 1338, 1249, 887, 790 cm -1. Elemental Analysis: calcd for C11H11NSBr2: C 38.05 H, 3.17 N 
4.03 S 9.22 Br 46.06, found C 38.42 H, 3.24 N 4.20 S 9.60 Br 45.19. 
 
 
M.P 163- 164 0C; 1H NMR (400 MHz, CDCl3) 1.94 (s, 3H), 3.47 (s, 3H), 4.36 (s, 1H), 5.03 (s, 
1H), 5.58 (s, 2H), 7.70 (t, J=7.6 Hz, 1H), 7.79 (t, J=7.9 Hz, 1H), 7.95 (d, J=8.5 Hz, 1H), 8.32 (d, 
J=8.1 Hz, 1H); 13C NMR (400 MHz, CDCl3) 19.10, 20.55, 55.70, 113.40, 116.78, 124.49, 128.68, 
129.99, 138.41, 142.40, 177.37. IR (thin film) ν max: 3410, 3375, 3363, 2924, 2360, 2337, 1465, 
1450, 1419, 1338, 1249, 887, 790 cm -1. Elemental Analysis: calcd for C12H14NSBr: C 50.88 H, 
4.96 N 4.96 S 11.30 Br 28.23, found C 49.83 H, 5.24 N 4.80 S 11.14 Br 27.36. 
90 
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The crude solid used for Claisen rearrangement without any further purification.  
 
 
M.P 238 - 240 0C (decomposed); 1H NMR (400 MHz, CDCl3) 3.41 (s, 3H), 3.59 (d, J=6.6 Hz, 
2H), 5.87 (d, J=5.9 Hz, 2H), 6.33 (m, J=7.8 Hz, 1H), 6.77 (d, J=17.2, 15.8 Hz, 1H), 7.31 (m, J=7.0 
Hz, 5H), 7.74 (t, J=7.6 Hz, 1H), 7.84 (t, J=7.8 Hz, 1H), 8.12 (d, J=8.4 Hz, 1H),8.24 (d, J=8.0 Hz, 
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1H); 13C NMR (400 MHz, CDCl3) 19.81, 50.67, 53.10, 116.78, 117.67, 124.49, 126.88, 128.85, 
128.86, 130.99, 134.41, 136.40, 141.67, 176.98. IR (thin film) ν max: 3375, 3294, 3263, 2924, 1672, 
1430, 987, 952, 771, 744, 690, 675, 617 cm -1. Elemental Analysis: calcd for C17H16NSBr: C 59.12 
H, 4.63 N 4.05 S 9.27 Br 23.15, found C 58.77 H, 4.63 N 4.03 S 9.52 Br 23.01. 
 
 
The crude solid used for Claisen rearrangement without any further purification. 
 
 
M.P 122 - 124 0C (decomposed);  1H NMR (400 MHz, CDCl3) 0.83 (s, CH3, 3H), 1.17 (d, J=8.9Hz, 
2H), 1.29 (d, J=16.6 Hz, 1H), 1.31 (s, CH3, 3H), 2.23 (q, J=17.9 Hz, 4H), 2.47 (m, J=4.4 Hz, 1H), 
3.45 (s, CH3, 3H), 3.47 (d, J=17.3 Hz, 1H), 5.04 (d, J=24.1 Hz, 1H), 5.47 (d, J=18.1 Hz, 2H), 7.70 
(t, J=7.6 Hz, 1H), 7.79 (t, J=7.8 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 8.33 (d, J=8.1 Hz, 1H); 13C NMR 
(400 MHz, CDCl3) 1.01, 18.94, 21.02, 25.87, 31.11, 31.50, 38.32, 40.42, 43.69, 53.42, 54.46, 
92 
116.58, 120.63, 124.51, 128.61, 129.85, 139.41, 141.34, 178.61. IR (thin film) ν max: 3228, 3178, 
3055, 1678, 1600, 1543, 1505, 1465, 1438, 1411, 1375, 1315, 1211, 999, 833, 759 cm -1. Elemental 
Analysis: calcd for C18H22NSBr: C 53.49 H, 6.05 N 3.85 S 8.81 Br 22.0, found C 53.73 H, 5.78 N 
3.99 S 8.85 Br 22.19. 
 
 
The crude solid used for Claisen rearrangement without any further purification 
 
 





M.P 183 - 185 0C (decomposed);  1H NMR (400 MHz, CDCl3) 1.11 (s, 3H), 2.33 (s, 3H), 3.63 (d, 
J=4.1 Hz, 2H), 4.95 (d, J=5.1 Hz, 2H), 5.21 (qt, J=17.8, 5.5 Hz, 2H), 5.95 (d, J=9.0 Hz, 2H), 6.55 
(d, J=9.2 Hz, 2H), 6.92 (t, J=7.4 Hz, 1H), 6.99 (t, J=7.3 Hz, 1H), 7.41 (d, J=8.4 Hz, 1H), 7.58 (d, 
J=7.9 Hz, 1H), 8.92 (s, NH, 1H); 13C NMR (400 MHz, CDCl3) 17.4, 24.0, 54.9, 69.7, 114.5, 119.3, 
122.6, 124.5, 125.4, 129.7, 130.6, 130.8, 131.7, 132.4, 140.9, 153.7, 168.9, 174.2; IR (thin film) ν 
max: 3411, 3375, 3228, 3178, 2068, 1705, 1658, 1543, 1505, 1465, 1438, 1411, 12555, 1015, 980, 
751 cm -1. Elemental Analysis: calcd for C20H21N2O2SBr: C 55.54 H, 4.86 N 6.84 S 7.40 Br 18.49, 
found C 53.35 H, 4.86 N 6.23 S 7.73 Br 18.31. 
 
 
M.P 159 - 161 0C;  1H NMR (400 MHz, CDCl3) 1.20 (t, J=7.2 Hz, 6H), 1.33 (s, 3H), 2.60 (d, J=4.6 
Hz, 2H), 3.51 (s, 3H), 4.13 (q, J=6.8 Hz, 4H), 5.62 (t, J=4.2 Hz, 2H), 5.73 (t, J=4.2 Hz, 2H), 7.75 
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(t, J=7.7 Hz, 1H), 7.84 (t, J=7.7 Hz, 1H), 7.97 (d, J=8.5 Hz, 1H), 8.23 (d, J=8.1 Hz, 1H); 13C NMR 
(400 MHz, CDCl3) 14.1, 17.4, 20.7, 42.9, 54.9, 55.6, 61.6, 119.3, 123.9, 125.4, 129.5, 129.7, 131.7, 
132.4, 140.9, 175.4, 176.7; IR (thin film) ν max: 3651, 3228, 3178, 2068, 1705, 1658, 1543, 1505, 
1465, 1438, 1411, 1375, 1315 cm -1. Elemental Analysis: calcd for C20H26NO4SBr: C 52.73 H, 
5.71 N 3.07 S 7.03 Br 17.55, found C 50.64 H, 5.48 N 3.03 S 7.21 Br 16.76. 
 
 
Brown colored semi solid;  1H NMR (400 MHz, CDCl3) 2.30 (s, 3H), 2.64 (app quartet, J=7.4 Hz, 
2H), 3.22 (t, J=7.8 Hz, 2H), 5.06 (d, J=10.2 Hz, 1H), 5.14 (d, J=17.1 Hz, 1H), 5.34 (d, J=10.6 Hz, 
2H), 5.76 (m, J=10.3 Hz, 2H), 5.9 (ddt, J=16.9, 10.3, 6.5 Hz, 1H), 6.13 (ddt, J=17.1, 10.3, 6.5 Hz, 
1H), 7.01 (d, J=8.2 Hz, 2H), 7.60 (d, J=8.2 Hz, 2H), 7.64 (t, J=7.8 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 
7.90 (d, J=8.4 Hz, 1H), 8.15 (d, J=8.0 Hz, 1H); 13C NMR (400 MHz, CDCl3) 17.45, 21.20, 29.70, 
39.08, 41.07, 51.92, 116.65, 119.88, 124.32, 125.75, 128.32, 128.40, 128.85, 129.00, 129.70, 
132.52, 138.89, 140.86, 143.95, 176.78. Elemental Analysis: calcd for C21H23NO3S2: C 62.82 H, 




Dark brown semi solid; 1H NMR (400 MHz, CDCl3) 2.31 (s, 3H), 2.69 (app quartet, J=6.7 Hz, 
4H), 4.25 (t, J=6.5 Hz, 1H), 5.01 (d, J=17.2 Hz, 1H), 5.09 (t, J=10.5 Hz, 2H), 5.31 (d, J=12.9 Hz, 
1H), 5.34 (d, J=10.6 Hz, 2H), 5.76 (m, J=10.3 Hz, 4H), 6.13 (ddt, J=17.2, 10.5, 5.1 Hz, 1H), 7.05 
(d, J=7.7 Hz, 2H), 7.69 (d, J=7.7 Hz, 2H), 7.64 (t, J=7.8 Hz, 3H), 7.726 (t, J=7.7 Hz, 1H), 8.06 (d, 
J=8.5 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H); 13C NMR (400 MHz, CDCl3) 21.26, 29.70, 39.08, 41.07, 
52.93, 117.87, 119.75, 120.29, 124.00, 126.01, 128.41, 128.68, 128.85, 129.56, 130.11, 132.52, 
138.82, 141.03, 144.05, 184.25. Elemental Analysis: calcd for C24H27NO3S2: C 65.28 H, 6.12 N 
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Natural product is a macromolecule produced by living organisms, and can be prepared 
from chemical synthesis. Natural product often possess a biological benefit to treat unmet medical 
condition. Natural product is a challenging synthetic target involving numerous complex organic 
transformations. In this work, the linear synthesis of C29-C34 moiety of fragment A of the 
Antascomicin B was highlighted through chemical reactions include an Delis Alder reaction, 
asymmetric transfer hydrogenation (ATH), epoxide ring opening reactions. Our asymmetric 
synthetic strategy designed and established for scale up from commercially available starting 
material. The synthetic route was established to achieve asymmetric compound in gram scale by 
more efficient and atom economic with compare to the previously developed method. 
Carbon-carbon bond formation is the important transformation in organic synthesis. Since 
the Claisen rearrangement, discovered various research groups drawn attention to make various 
medication for carbon-carbon bond formation.  In this work, we describes novel methodologies of 
preparing 2-butenyl benzothiazole derivatives using aza-Claisen rearrangement, through N, S-
ketene acetals intermediates. The precursor N-allyl-N, S-ketene acetals were prepared in situ from 
the reaction of N-allyl benzothiazolium salts.  N-allyl benzothiazolium salts synthesized by simply 
alkylated 2-methyl benzothiazole with various allyl bromide derivatives. Despite of the traditional 
approaches, our proposed synthetic methodology of N, S-ketene acetals that requires only weak 
base, possesses broad functional group compatibility, and require no cryogenic conditions.  
 
  
 
 
